What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2021-03-30 compared with 2020-04-06 · 1739 added, 1577 removed, 83 unchanged (98% of the section changed)

10 unchanged sentences

uncertainties.

business is subject to numerous risks and uncertainties that you should consider before investing in our company, as fully described

The principal factors and uncertainties that make investing in our company risky include, among others:

Operating and Business Risks

business is subject to risks arising from epidemic diseases, such as the recent outbreak of the COVID-19 illness.

recent outbreak of the Coronavirus Disease 2019, or COVID-19, which has been declared by the World Health Organization

to be a “public health emergency of international concern,”

has spread across the globe and is impacting worldwide

economic activity.

A public health epidemic, including COVID-19, poses the risk that we or our employees, contractors, suppliers,

and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns

that may be requested or mandated by governmental authorities.

While it is not possible at this time to estimate the impact that

COVID-19 could have on our business, the continued spread of COVID-19 and the measures taken by the governments of countries affected

could disrupt the supply chain and adversely impact our business, financial condition or results of operations.

The COVID-19 outbreak

and mitigation measures may also have an adverse impact on global economic conditions which could have an adverse effect on our

business and financial condition.

The extent to which the COVID-19 outbreak impacts our results will depend on future developments

that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus

and the actions to contain its impact.

limited operating history makes it difficult for us to evaluate our future business prospects and make decisions based on those

estimates of our future performance .

did not begin operations of our business through AHS until May 2015.

business is subject to risks arising from epidemic diseases, such as the recent outbreak

of the COVID-19 illness.

limited operating history makes it difficult for us to evaluate our future business prospects

and make decisions based on those estimates of our future performance.

results of operations have not resulted in profitability and we may not be able to achieve

profitability going forward.

depend upon key personnel and need additional personnel.

we have several consulting contracts with related parties in China.

The loss of such

customers could adversely impact our financial condition and results of operations.

auditors have issued a “Going Concern”

audit opinion.

must effectively manage the growth of our operations, or our company will suffer.

business requires substantial capital, and if we are unable to maintain adequate financing

sources our profitability and financial condition will suffer and jeopardize our ability

to continue operations.

revenue and results of operations may suffer if we are unable to attract new clients,

continue to engage existing clients, or sell additional products and services.

prospects will suffer if we are not able to hire, train, motivate, manage, and retain

a significant number of highly skilled employees.

liability claims may adversely affect our business.

accordance with our strategic development policy, we may invest in companies for strategic

reasons and may not realize a return on our investments.

growing operations in the PRC could expose us to risks that could have an adverse effect

on our costs of operations.

face intense competition which could cause us to lose market share.

we are unable to obtain and maintain sufficient intellectual property protection for

our products and product candidates, or if the scope of the intellectual property protection

obtained is not sufficiently broad, our competitors could develop and commercialize product

candidates similar or identical to ours, and our ability to successfully commercialize

our product candidates may be impaired.

may face uncertainty and difficulty in obtaining and enforcing our patents and other

proprietary rights.

may not be able to protect our intellectual property rights throughout the world.

terms may be inadequate to protect our competitive position on our product candidates

for an adequate amount of time.

and maintaining patent protection depends on compliance with various procedural, document

submission, fee payment and other requirements imposed by governmental patent agencies,

and any patent protection we may obtain in the future could be reduced or eliminated

for non-compliance with these requirements.

is difficult and costly to protect our proprietary rights, and we may not be able to

ensure their protection.

If we fail to protect or enforce our intellectual property rights

adequately or secure rights to patents of others, the value of our intellectual property

rights would diminish.

we fail to comply with our obligations in the agreements under which we license intellectual

property rights from third parties or otherwise experience disruptions to our business

relationships with our licensors, we could lose intellectual property rights that are

important to our business.

may be subject to claims challenging the inventorship of patents and other intellectual

any of our trade secrets, know-how or other proprietary information is disclosed, the

value of our trade secrets, know-how and other proprietary rights would be significantly

impaired and our business and competitive position would suffer.

may incur substantial costs as a result of litigation or other proceedings relating to

patent and other intellectual property rights and we may be unable to protect our rights

to, or use of, our technology.

or compromises of our information security systems or our information technology systems

or infrastructure could result in exposure of private information, disruption of our

business and damage to our reputation, which could harm our business, results of operation

and financial condition.

may be exposed to liabilities under the Foreign Corrupt Practices Act, and any determination

that we violated the Foreign Corrupt Practices Act or Chinese anti-corruption law could

have a material adverse effect on our business.

Factors Related to Clinical and Commercialization Activity

may not be able to file INDs to commence additional clinical trials on the timelines

we expect, and even if we are able to do so, the FDA may not permit us to proceed.

have limited experience in conducting clinical trials.

in the commencement, enrollment, and completion of clinical testing could result in increased

costs to us and delay or limit our ability to obtain regulatory approval for our product

success depends upon the viability of our product candidates and we cannot be certain

any of them will receive regulatory approval to be commercialized.

the results of earlier pre-clinical studies or clinical trials are not necessarily predictive

of future results, any product candidate we advance into clinical trials may not have

favorable results in later clinical trials or receive regulatory approval.

business faces significant government regulation, and there is no guarantee that our

product candidates will receive regulatory approval.

if our product candidates receive regulatory approval, we may still face future development

and regulatory difficulties.

we or current or future collaborators, manufacturers, or service providers fail to comply

with healthcare laws and regulations, we or they could be subject to enforcement actions

and substantial penalties, which could affect our ability to develop, market and sell

our products and may harm our reputation.

cell based therapies we develop may become subject to unfavorable pricing regulations,

third party coverage and reimbursement practices or healthcare reform initiatives, thereby

harming our business.

healthcare industry is heavily regulated in the U.S.

at the federal, state, and local

levels, and our failure to comply with applicable requirements may subject us to penalties

and negatively affect our financial condition.

ability to obtain reimbursement or funding from the federal government may be impacted

by possible reductions in federal spending.

Related to Doing Business in China

we become directly subject to the recent scrutiny, criticism and negative publicity involving

certain U.S.-listed Chinese companies, we may have to expend significant resources to

investigate and resolve the matter which could harm our business operations, stock price

and reputation and could result in a loss of your investment in our stock, especially

if such matter cannot be addressed and resolved quickly.

changes in political and economic policies of the PRC government could impede the overall

economic growth of China, which could reduce the demand for our products and damage our

● Uncertainties

with respect to the PRC legal system could limit the legal protections available to you

PRC government exerts substantial influence over the manner in which we must conduct

our business activities.

may be unable to complete a business combination transaction efficiently or on favorable

terms due to complicated merger and acquisition regulations implemented on September

the current Enterprise Income Tax, or EIT, law, we may be classified as a “resident

enterprise”

Such classification will likely result in unfavorable tax

consequences to us and our non- PRC stockholders.

may be subject to fines and legal sanctions if we or our Chinese employees fail to comply

with PRC regulations relating to employee stock options granted by overseas listed companies

to PRC citizens.

new M&A Rules establish more complex procedures for some acquisitions of Chinese

companies by foreign investor which could make it more difficult for us to pursue growth

through acquisitions in China.

control of currency conversion and future movements in exchange rates may adversely affect

our operations and financial results.

Related to Our Securities

price of our common stock may be volatile and fluctuate substantially, which could result

in substantial losses for our stockholders.

sales of our common stock or securities convertible or exchangeable for our common stock

may cause our stock price to decline.

may experience dilution of your ownership interests because of the future issuance of

additional shares of our common or preferred stock or other securities that are convertible

into or exercisable for our common or preferred stock.

ability of our Board of Directors to issue additional stock may prevent or make more

difficult certain transactions, including a sale or merger.

are a “smaller reporting company,”

and we cannot be certain if the reduced

disclosure requirements applicable to smaller reporting companies will make our common

stock less attractive to investors.

securities or industry analysts do not publish research or reports about our business,

or if they issue an adverse or misleading opinion regarding our stock, our stock price

and trading volume could decline.

officers, directors and principal stockholders own a significant percentage of our stock

and will be able to exert significant control over matters subject to stockholder approval.

may be exposed to additional risks as a result of “going public”

of a reverse acquisition transaction.

do not anticipate paying dividends on our common stock, and investors may lose the entire

amount of their investment.

regulatory requirements, including those contained in and issued under the Sarbanes-Oxley

Act of 2002, may make it difficult for us to retain or attract qualified officers and

directors, which could adversely affect the management of our business and our ability

to obtain or retain listing of our common stock on a national securities exchange.

we cannot satisfy, or continue to satisfy, the initial listing requirements and other

rules of the Nasdaq Capital Market, our securities may be delisted, which could negatively

impact the price of our securities and your ability to sell them.

could be subject to securities class action litigation.

Operating and Business Risks

Our business is

subject to risks arising from epidemic diseases, such as the recent outbreak of the COVID-19 illness.

The recent outbreak of

the Coronavirus Disease 2019, or COVID-19, which has been declared by the World Health Organization to be a “public

health emergency of international concern,”

has spread across the globe and is impacting worldwide economic activity.

several vaccines have been developed, a public health epidemic, including COVID-19, poses the risk that we or our employees, contractors,

suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including

due to shutdowns that may be requested or mandated by governmental authorities.

While it is not possible at this time to estimate

the impact that COVID-19 could have on our business, the continued spread of COVID-19 and the measures taken by the governments

of countries affected could disrupt the supply chain and adversely impact our business, financial condition or results of operations.

The COVID-19 outbreak and mitigation measures may also have an adverse impact on global economic conditions which could have an

adverse effect on our business and financial condition.

The extent to which the COVID-19 outbreak impacts our results will depend

on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning

the severity of the virus and the actions to contain its impact.

Our limited operating history makes it difficult

for us to evaluate our future business prospects and make decisions based on those estimates of our future performance .

We did not begin operations

of our business through AHS until May 2015.

We have a limited operating history and limited revenue.

As a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data.

on the historical results may not be representative of the results we will achieve, particularly in our combined form.

of the uncertainties related to our lack of historical operations, we may be hindered in our ability to anticipate and timely

adapt to increases or decreases in revenues or expenses.

If we make poor budgetary decisions as a result of unreliable historical

data, we could be less profitable or incur losses, which may result in a decline in our stock price.

results of operations have not resulted in profitability and we may not be able to achieve profitability going forward.

incurred a net loss amounting to $8,052,296 for the year ended December 31, 2018 and a net loss amounting to $18,070,161 for the

year ended December 31, 2019.

As a consequence, it is difficult,

if not impossible, to forecast our future results based upon our historical data.

Reliance on the historical results may not be

representative of the results we will achieve, particularly in our combined form.

Because of the uncertainties related to our lack

of historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in revenues

If we make poor budgetary decisions as a result of unreliable historical data, we could be less profitable or incur

losses, which may result in a decline in our stock price.

Our results of operations have not resulted

in profitability and we may not be able to achieve profitability going forward.

We incurred a net

loss amounting to $12,679,438 for the year ended December 31, 2020 and a net loss amounting to $18,070,161 for the year ended

December 31, 2019.

If we incur additional significant losses, our stock price may decline, perhaps significantly.

2 unchanged sentences

There is no assurance

that we will be successful in executing our business plan or that even if we successfully implement our business plan, that we

will be able to curtail our losses now or in the future.

Further, as we are a new enterprise, we expect that net losses will continue.

depend upon key personnel and need additional personnel.

success depends on the continuing services of Wenzhao Lu, our Chairman of the Board, and David Jin, Meng Li and Luisa Ingargiola,

our executive officers.

that we will be successful in executing our business plan or that even if we successfully implement our business plan, that

we will be able to curtail our losses now or in the future.

Further, as we are a new enterprise, we expect that net losses

will continue.

We depend upon key personnel and need additional

Our success depends on

the continuing services of Wenzhao Lu, our Chairman of the Board, and David Jin, Meng Li and Luisa Ingargiola, our executive officers.

The loss of Mr.

Ingargiola could have a material and adverse effect on our

business operations.

Additionally, the success of our operations will largely depend upon our ability to successfully attract

and maintain competent and qualified key management personnel.

As with any company with limited resources, there can be no guaranty

that we will be able to attract such individuals or that the presence of such individuals will necessarily translate into profitability

Our inability to attract and retain key personnel may materially and adversely affect our business operations.

we have several consulting contracts with related parties in China.

The loss of such customers could adversely impact our financial

condition and results of operations.

the year ended December 31, 2019, we recognized an aggregate of $1,546,305 in revenue, of which $355,544 was generated from related

Ingargiola could have a material and adverse effect on our business operations.

Additionally,

the success of our operations will largely depend upon our ability to successfully attract and maintain competent and qualified

key management personnel.

As with any company with limited resources, there can be no guaranty that we will be able to attract

such individuals or that the presence of such individuals will necessarily translate into profitability for us.

Our inability to

attract and retain key personnel may materially and adversely affect our business operations.

Currently, we have several consulting contracts

with related parties in China.

The loss of such customers could adversely impact our financial condition and results of operations.

During the year ended

December 31, 2020, we recognized an aggregate of $1,377,762 in revenue, of which $170,908 was generated from related parties.

During the year ended December 31, 2019, we recognized an aggregate of $1,546,305 in revenue, of which $355,544 was generated

4 unchanged sentences

material adverse effect on our financial condition and our results of operations.

auditors have issued a “Going Concern”

audit opinion.

independent auditors have indicated, in their report on our December 31, 2019 consolidated financial statements, that there is

substantial doubt about our ability to continue as a going concern.

Our auditors have issued an audit opinion

which raises substantial doubt about our ability to continue as a going concern.

Our independent auditors

have indicated, in their report on our December 31, 2020 consolidated financial statements, that there is substantial doubt about

our ability to continue as a going concern.

We had an accumulated deficit of $42,041,375 at December 31, 2020.

We have a limited operating history, incurred recurring net loss and negative cash flows from operating activities, and

our continued growth is dependent upon the continuation of providing medical consulting services to our related parties, generating

rental revenue from our income-producing real estate property in New Jersey and generating revenue from development services and

sales of developed products;

hence generating revenues, and obtaining additional financing to fund future obligations and pay

liabilities arising from normal business operations.

Our ability to continue as a going concern is dependent on our ability to

raise additional capital, implement our business plan, and generate significant revenues.

There are no assurances that we will

be successful in our efforts to generate significant revenues, maintain sufficient cash balance or report profitable operations

or to continue as a going concern.

We plan on raising capital through the sale of equity to implement our business plan.

there is no assurance these plans will be realized and that any additional financings will be available to our company on satisfactory

terms and conditions, if any.

must effectively manage the growth of our operations, or our company will suffer.

manage our growth, we believe we must continue to implement and improve our services and products.

We may not have adequately

evaluated the costs and risks associated with our planned expansion, and our systems, procedures, and controls may not be adequate

to support our operations.

In addition, our management may not be able to achieve the rapid execution necessary to successfully

offer our products and services and implement our business plan on a profitable basis.

The success of our future operating activities

will also depend upon our ability to expand our support system to meet the demands of our growing business.

Any failure by our

management to effectively anticipate, implement, and manage changes required to sustain our growth would have a material adverse

effect on our business, financial condition, and results of operations.

business requires substantial capital, and if we are unable to maintain adequate financing sources our profitability and financial

condition will suffer and jeopardize our ability to continue operations.

connection with the strategic development portion of our business, we will need significant capital in order to implement acquisitions

of technologies.

In addition, we will need a significant amount of capital in order to fully implement our advisory business,

maintain our rental property and further develop our exosome business.

If we are unable to maintain adequate financing or other

sources of capital are not available, we could be forced to suspend, curtail or reduce our operations, which could harm our revenues,

profitability, financial condition and business prospects.

revenue and results of operations may suffer if we are unable to attract new clients, continue to engage existing clients, or

sell additional products and services.

presently derive our revenue from providing medical related consulting services to related parties and generating rental revenue

from our income-producing real estate property in New Jersey.

Our growth therefore depends on our ability to attract new clients,

maintain existing clients and properties and sell additional products and services to existing clients.

This depends on our ability

to understand and anticipate market and pricing trends and our clients’

needs and our ability to deliver consistent, reliable,

high-quality services.

Our failure to engage new clients, continue to re-engage with our existing clients or cross-sell additional

services could materially and adversely affect our operating results.

prospects will suffer if we are not able to hire, train, motivate, manage, and retain a significant number of highly skilled employees.

only recently commenced business and we presently generate medical related consulting services from related parties and generate

rental revenue from our income-producing real estate property in New Jersey.

On the consulting side, Wenzhao Lu, our Chairman

and significant shareholder, is the Chairman of each of the clients in which we have provided consulting services.

success depends upon our ability to hire, train, motivate, manage, and retain a significant number of highly skilled employees,

particularly research analysts, technical experts, and sales and marketing staff.

We will experience competition for professional

personnel in each of our business lines.

Hiring, training, motivating, managing, and retaining employees with the skills we need

is time consuming and expensive.

Any failure by us to address our staffing needs in an effective manner could hinder our ability

to continue to provide high-quality products and services and to grow our business.

liability claims may adversely affect our business.

services, which may include recommendations and advice to organizations regarding complex business and operational processes and

regulatory and compliance issues may give rise to liability claims by our clients or by third parties who bring claims against

Healthcare organizations often are the subject of regulatory scrutiny and litigation, and we also may become the

subject of such litigation based on our advice and services.

Any such litigation, whether or not resulting in a judgment against

us, may adversely affect our reputation and could have a material adverse effect on our financial condition and results of operations.

We may not have adequate insurance coverage for claims against us.

accordance with our strategic development policy, we may invest in companies for strategic reasons and may not realize a return

on our investments.

time to time, we may make investments in companies.

These investments may be for strategic objectives to support our key business

initiatives but may also be standalone investments or acquisitions.

Such investments or acquisitions could include equity or debt

instruments in private companies, many of which may not be marketable at the time of our initial investment.

These companies may

range from early-stage companies that are often still defining their strategic direction to more mature companies with established

revenue streams and business models.

We have a limited

operating history, incurred recurring net loss and negative cash flows from operating activities, and our continued growth is dependent

upon the continuation of providing medical consulting services to our related parties, generating rental revenue from our income-producing

real estate property in New Jersey and generating revenue from development services and sales of developed products;

hence generating

revenues, and obtaining additional financing to fund future obligations and pay liabilities arising from normal business operations.

Our ability to continue as a going concern is dependent on our ability to raise additional capital, implement our business plan,

and generate significant revenues.

There are no assurances that we will be successful in our efforts to generate significant revenues,

maintain sufficient cash balance or report profitable operations or to continue as a going concern.

We plan on raising capital

through the sale of equity to implement our business plan.

However, there is no assurance these plans will be realized and that

any additional financings will be available to our company on satisfactory terms and conditions, if any.

We must effectively manage the growth of

our operations, or our company will suffer.

To manage our growth, we

believe we must continue to implement and improve our services and products.

We may not have adequately evaluated the costs and

risks associated with our planned expansion, and our systems, procedures, and controls may not be adequate to support our operations.

In addition, our management may not be able to achieve the rapid execution necessary to successfully offer our products and services

and implement our business plan on a profitable basis.

The success of our future operating activities will also depend upon our

ability to expand our support system to meet the demands of our growing business.

Any failure by our management to effectively

anticipate, implement, and manage changes required to sustain our growth would have a material adverse effect on our business,

financial condition, and results of operations.

Our business requires substantial capital,

and if we are unable to maintain adequate financing sources our profitability and financial condition will suffer and jeopardize

our ability to continue operations.

In connection with the

strategic development portion of our business, we will need significant capital in order to implement acquisitions of technologies.

In addition, we will need a significant amount of capital in order to fully implement our advisory business, maintain our rental

property and further develop our exosome business.

If we are unable to maintain adequate financing or other sources of capital

are not available, we could be forced to suspend, curtail or reduce our operations, which could harm our revenues, profitability,

financial condition and business prospects.

Our revenue and results of operations may

suffer if we are unable to attract new clients, continue to engage existing clients, or sell additional products and services.

We presently derive our

revenue from providing medical related consulting services to related parties and generating rental revenue from our income-producing

real estate property in New Jersey.

Our growth therefore depends on our ability to attract new clients, maintain existing clients

and properties and sell additional products and services to existing clients.

This depends on our ability to understand and anticipate

market and pricing trends and our clients’

needs and our ability to deliver consistent, reliable, high-quality services.

Our failure to engage new clients, continue to re-engage with our existing clients or cross-sell additional services could materially

and adversely affect our operating results.

Our prospects will suffer if we are not

able to hire, train, motivate, manage, and retain a significant number of highly skilled employees.

We only recently commenced

business and we presently generate medical related consulting services from related parties and generate rental revenue from our

income-producing real estate property in New Jersey.

On the consulting side, Wenzhao Lu, our Chairman and significant shareholder,

is the Chairman of each of the clients in which we have provided consulting services.

Our future success depends upon our ability

to hire, train, motivate, manage, and retain a significant number of highly skilled employees, particularly research analysts,

technical experts, and sales and marketing staff.

We will experience competition for professional personnel in each of our business

Hiring, training, motivating, managing, and retaining employees with the skills we need is time consuming and expensive.

Any failure by us to address our staffing needs in an effective manner could hinder our ability to continue to provide high-quality

products and services and to grow our business.

Potential liability claims may adversely

affect our business.

Our services, which may

include recommendations and advice to organizations regarding complex business and operational processes and regulatory and compliance

issues may give rise to liability claims by our clients or by third parties who bring claims against our clients.

Healthcare organizations

often are the subject of regulatory scrutiny and litigation, and we also may become the subject of such litigation based on our

advice and services.

Any such litigation, whether or not resulting in a judgment against us, may adversely affect our reputation

and could have a material adverse effect on our financial condition and results of operations.

We may not have adequate insurance

coverage for claims against us.

In accordance with our strategic development

policy, we may invest in companies for strategic reasons and may not realize a return on our investments.

From time to time, we

may make investments in companies.

These investments may be for strategic objectives to support our key business initiatives but

may also be standalone investments or acquisitions.

Such investments or acquisitions could include equity or debt instruments

in private companies, many of which may not be marketable at the time of our initial investment.

These companies may range from

early-stage companies that are often still defining their strategic direction to more mature companies with established revenue

streams and business models.

The success of these companies may depend on product development, market acceptance, operational

6 unchanged sentences

we may be required to write down the investments to their fair value and recognize the related write-down as an investment loss.

growing operations in the PRC could expose us to risks that could have an adverse effect on our costs of operations.

client base is presently located in the PRC.

Our growing operations in the PRC could

expose us to risks that could have an adverse effect on our costs of operations.

Our client base is presently

located in the PRC.

We intend to grow this client base in the PRC as well as the United States.

result, we expect to continue to add personnel in the PRC.

With a significant focus of our operations in the PRC, our reliance

on a workforce in the PRC exposes us to disruptions in the business, political, and economic environment in that region.

of a stable political environment between the PRC and the United States is important to our operations, and any disruption in

this relationship may directly negatively affect our operations.

Our operations in the PRC require us to comply with complex local

laws and regulatory requirements and expose us to foreign currency exchange rate risk.

Our operations may also be subject to reduced

or inadequate protection of our intellectual property rights, and security breaches.

Further, it may be difficult to transfer

funds from our Chinese operations to our company.

Negative developments in any of these areas could increase our costs of operations

or otherwise harm our business.

face intense competition which could cause us to lose market share.

the healthcare markets in the United States and the People’s Republic of China, we will compete with large healthcare providers

who have more significant financial resources, established market positions, long-standing relationships, and who have more significant

name recognition, technical, marketing, sales, distribution, financial and other resources than we do.

The resources available

to our competitors to develop new services and products and introduce them into the marketplace exceed the resources currently

available to us.

This intense competitive environment may require us to make changes in our services, products, pricing, licensing,

distribution, or marketing to develop a market position.

we are unable to obtain and maintain sufficient intellectual property protection for our products and product candidates, or if

the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize

product candidates similar or identical to ours, and our ability to successfully commercialize our product candidates may be impaired.

success will depend in large part on our ability to obtain, maintain, and defend patents on our product candidates, obtain licenses

to use third-party technologies, protect our trade secrets, and operate without infringing the proprietary rights of others.

is the case with other biopharmaceutical companies, our success depends on our ability to protect and defend intellectual property

we own or license, particularly patents, in the United States and other countries with respect to our product candidates and technology.

We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product

and enforcing biopharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all

necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications,

at a reasonable cost or in a timely manner.

It is also possible that we will fail to identify patentable aspects of our research

and development output before it is too late to obtain patent protection.

We may not have the right to control the preparation,

filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties.

Therefore, these

patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological

and factual questions and has in recent years been the subject of much litigation.

In addition, the laws of foreign countries

may not protect our rights to the same extent as the laws of the United States, or vice versa.

Further, we may not be aware of

all third-party intellectual property rights potentially relating to our product candidates.

Publications of discoveries in the

scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions

are typically not published until 18 months after filing or, in some cases, not at all.

Therefore, we cannot know with certainty

whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first

to file for patent protection of such inventions.

As a result, the issuance, scope, validity, enforceability and commercial value

of our patent rights are highly uncertain.

we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the

USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings

challenging our patent rights or the patent rights of others.

An adverse determination in any such submission, proceeding or litigation

could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete

As a result, we expect to continue

to add personnel in the PRC.

With a significant focus of our operations in the PRC, our reliance on a workforce in the PRC exposes

us to disruptions in the business, political, and economic environment in that region.

Maintenance of a stable political environment

between the PRC and the United States is important to our operations, and any disruption in this relationship may directly negatively

affect our operations.

Our operations in the PRC require us to comply with complex local laws and regulatory requirements and expose

us to foreign currency exchange rate risk.

Our operations may also be subject to reduced or inadequate protection of our intellectual

property rights, and security breaches.

Further, it may be difficult to transfer funds from our Chinese operations to our company.

Negative developments in any of these areas could increase our costs of operations or otherwise harm our business.

We face intense competition which could cause us to lose market

In the healthcare markets

in the United States and the People’s Republic of China, we will compete with large healthcare providers who have more significant

financial resources, established market positions, long-standing relationships, and who have more significant name recognition,

technical, marketing, sales, distribution, financial and other resources than we do.

The resources available to our competitors

to develop new services and products and introduce them into the marketplace exceed the resources currently available to us.

intense competitive environment may require us to make changes in our services, products, pricing, licensing, distribution, or

marketing to develop a market position.

If we are unable to obtain and maintain

sufficient intellectual property protection for our products and product candidates, or if the scope of the intellectual property

protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical

to ours, and our ability to successfully commercialize our product candidates may be impaired.

Our success will depend

in large part on our ability to obtain, maintain, and defend patents on our product candidates, obtain licenses to use third-party

technologies, protect our trade secrets, and operate without infringing the proprietary rights of others.

As is the case with other

biopharmaceutical companies, our success depends on our ability to protect and defend intellectual property we own or license,

particularly patents, in the United States and other countries with respect to our product candidates and technology.

protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates.

Obtaining and enforcing

biopharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or

desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a

reasonable cost or in a timely manner.

It is also possible that we will fail to identify patentable aspects of our research and

development output before it is too late to obtain patent protection.

We may not have the right to control the preparation, filing

and prosecution of patent applications, or to maintain the rights to patents licensed to third parties.

Therefore, these patents

and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

The patent position of

biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions

and has in recent years been the subject of much litigation.

In addition, the laws of foreign countries may not protect our rights

to the same extent as the laws of the United States, or vice versa.

Further, we may not be aware of all third-party intellectual

property rights potentially relating to our product candidates.

Publications of discoveries in the scientific literature often

lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published

until 18 months after filing or, in some cases, not at all.

Therefore, we cannot know with certainty whether we were the first

to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection

of such inventions.

As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly

Moreover, we may be subject

to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become

involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging

our patent rights or the patent rights of others.

An adverse determination in any such submission, proceeding or litigation could

reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete

directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party

3 unchanged sentences

or future product candidates.

addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents

may be challenged in the courts or patent offices in the United States and abroad.

Such challenges may result in loss of exclusivity

or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could

limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration

of the patent protection of our product candidates.

Given the amount of time required for the development, testing and regulatory

review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are

commercialized.

As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing

drugs similar or identical to ours.

may face uncertainty and difficulty in obtaining and enforcing our patents and other proprietary rights.

can be no assurance that any patent applications we file or license will be approved, or that challenges will not be instituted

against the validity or enforceability of any patent licensed-in or owned by us.

Our pending and future patent applications may

not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others

from commercializing competitive product candidates.

Even if our patent applications issue as patents, they may not issue in a

form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with

any competitive advantage.

Our competitors may be able to circumvent our patents by developing similar or alternative product

candidates in a non-infringing manner.

In addition, the issuance

of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the

courts or patent offices in the United States and abroad.

Such challenges may result in loss of exclusivity or freedom to operate

or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop

others from using or commercializing similar or identical product candidates, or limit the duration of the patent protection of

our product candidates.

Given the amount of time required for the development, testing and regulatory review of new product candidates,

patents protecting such candidates might expire before or shortly after such candidates are commercialized.

As a result, our patent

portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.

We may face uncertainty and difficulty in

obtaining and enforcing our patents and other proprietary rights.

There can be no assurance

that any patent applications we file or license will be approved, or that challenges will not be instituted against the validity

or enforceability of any patent licensed-in or owned by us.

Our pending and future patent applications may not result in patents

being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing

competitive product candidates.

Even if our patent applications issue as patents, they may not issue in a form that will provide

us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage.

Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing

The cost of litigation to uphold the validity and prevent infringement of a patent is substantial.

Furthermore, there can be no assurance that others will not independently develop substantially equivalent technologies not covered

by patents to which we have rights or obtain access to our know-how.

In addition, the laws of certain countries may not adequately

protect our intellectual property.

Our competitors may possess or obtain patents on products or processes that are necessary or

useful to the development, use, or manufacture of our product candidates.

There can also be no assurance that our proposed technology

will not infringe upon patents or proprietary rights owned by others, with the result that others may bring infringement claims

against us and require us to license such proprietary rights, which may not be available on commercially reasonable terms, if

Any such litigation, if instituted, could have a material adverse effect, potentially including monetary penalties, diversion

of management resources, and injunction against continued manufacture, use, or sale of certain products or processes.

rely upon non-patented proprietary know-how.

There can be no assurance that we can adequately protect our rights in such non-patented

proprietary know-how, or that others will not independently develop substantially equivalent proprietary information or techniques

or gain access to our proprietary know-how.

Furthermore, there can

be no assurance that others will not independently develop substantially equivalent technologies not covered by patents to which

we have rights or obtain access to our know-how.

In addition, the laws of certain countries may not adequately protect our intellectual

Our competitors may possess or obtain patents on products or processes that are necessary or useful to the development,

use, or manufacture of our product candidates.

There can also be no assurance that our proposed technology will not infringe upon

patents or proprietary rights owned by others, with the result that others may bring infringement claims against us and require

us to license such proprietary rights, which may not be available on commercially reasonable terms, if at all.

Any such litigation,

if instituted, could have a material adverse effect, potentially including monetary penalties, diversion of management resources,

and injunction against continued manufacture, use, or sale of certain products or processes.

We rely upon non-patented

proprietary know-how.

There can be no assurance that we can adequately protect our rights in such non-patented proprietary know-how,

or that others will not independently develop substantially equivalent proprietary information or techniques or gain access to

our proprietary know-how.

Any of the foregoing events could have a material adverse effect on us.

if any of our trade secrets, know-how or other proprietary information were to be disclosed, or misappropriated, the value of

our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position

would suffer.

September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law.

The Leahy-Smith Act includes

a number of significant changes to U.S.

These include provisions that affect the way patent applications will be prosecuted

and may also affect patent litigation.

In particular, under the Leahy-Smith Act, the United States transitioned in March 2013

to a “first to file”

In addition, if any of our trade

secrets, know-how or other proprietary information were to be disclosed, or misappropriated, the value of our trade secrets, know-how

and other proprietary rights would be significantly impaired and our business and competitive position would suffer.

In September 2011, the

Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law.

The Leahy-Smith Act includes a number of significant

changes to U.S.

These include provisions that affect the way patent applications will be prosecuted and may also affect

patent litigation.

In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a “first to

system in which the first inventor to file a patent application will be entitled to the patent.

Third parties are allowed to submit prior art before the issuance of a patent by the U.S.

Patent and Trademark Office, or USPTO,

and may become involved in opposition, derivation, post-grant and inter partes review, or interference proceedings challenging

our patent rights.

An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate,

our patent rights, which could adversely affect our competitive position.

USPTO has developed new and untested regulations and procedures to govern the full implementation of the Leahy-Smith Act, and

many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the “first-to-file”

provisions, only became effective in March 2013.

The Leahy-Smith Act has also introduced procedures that may make it easier for

third parties to challenge issued patents, as well as to intervene in the prosecution of patent applications.

Finally, the Leahy-Smith

Act contains new statutory provisions that still require the USPTO to issue new regulations for their implementation, and it may

take the courts years to interpret the provisions of the new statute.

Accordingly, it is not clear what, if any, impact the Leahy-Smith

Act will have on the operation of our business.

The Leahy-Smith Act and its implementation could increase the uncertainties and

costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

may not be able to protect our intellectual property rights throughout the world.

prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive,

and our intellectual property rights in some countries outside the United States may be less extensive than those in the United

In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal

and state laws in the United States.

Consequently, we may not be able to prevent third parties from practicing our inventions

in all countries outside the United States, or from selling or importing products made using our inventions in and into the United

States or other jurisdictions.

Competitors may use our technologies in jurisdictions where we do not obtain patent protection

to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement

is not as strong as that in the United States.

These products may compete with our products and our patents or other intellectual

property rights may not be effective or sufficient to prevent them from competing.

companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.

The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade

secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it

difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights

Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial

costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated

or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against

We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially

Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain

a significant commercial advantage from the intellectual property that we develop or license.

terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

have a limited lifespan.

In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is

generally 20 years from its earliest U.S.

Third parties are allowed

to submit prior art before the issuance of a patent by the U.S.

Patent and Trademark Office, or USPTO, and may become involved

in opposition, derivation, post-grant and inter partes review, or interference proceedings challenging our patent rights.

An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent

rights, which could adversely affect our competitive position.

The USPTO has developed

new and untested regulations and procedures to govern the full implementation of the Leahy-Smith Act, and many of the substantive

changes to patent law associated with the Leahy-Smith Act, and in particular, the “first-to-file”

provisions, only

became effective in March 2013.

The Leahy-Smith Act has also introduced procedures that may make it easier for third parties to

challenge issued patents, as well as to intervene in the prosecution of patent applications.

Finally, the Leahy-Smith Act contains

new statutory provisions that still require the USPTO to issue new regulations for their implementation, and it may take the courts

years to interpret the provisions of the new statute.

Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will

have on the operation of our business.

The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding

the prosecution of our patent applications and the enforcement or defense of our issued patents.

We may not be able to protect our intellectual

property rights throughout the world.

Filing, prosecuting and

defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual

property rights in some countries outside the United States may be less extensive than those in the United States.

the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in

the United States.

Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside

the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.

Competitors may use our technologies in jurisdictions where we do not obtain patent protection to develop their own products and

may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in

the United States.

These products may compete with our products and our patents or other intellectual property rights may not be

effective or sufficient to prevent them from competing.

Many companies have

encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.

The legal systems

of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other

intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to

stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.

to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert

our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted

narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us.

not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.

Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant

commercial advantage from the intellectual property that we develop or license.

Patent terms may be inadequate to protect

our competitive position on our product candidates for an adequate amount of time.

Patents have a limited

In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years

from its earliest U.S.

non-provisional filing date.

Various extensions may be available, but the life of a

patent, and the protection it affords, is limited.

Even if patents covering our product candidates are obtained, once the patent

life has expired, we may be open to competition from competitive products, including generics or biosimilars.

Given the amount

of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates

might expire before or shortly after such candidates are commercialized.

As a result, any patents we may obtain may not provide

us with sufficient rights to exclude others from commercializing products similar or identical to ours.

and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements

imposed by governmental patent agencies, and any patent protection we may obtain in the future could be reduced or eliminated

for non-compliance with these requirements.

maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to

be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime

of the patents and/or applications.

Various extensions may be available, but the life of a patent, and the protection

it affords, is limited.

Even if patents covering our product candidates are obtained, once the patent life has expired, we may

be open to competition from competitive products, including generics or biosimilars.

Given the amount of time required for the

development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or

shortly after such candidates are commercialized.

As a result, any patents we may obtain may not provide us with sufficient rights

to exclude others from commercializing products similar or identical to ours.

Obtaining and maintaining patent protection

depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental

patent agencies, and any patent protection we may obtain in the future could be reduced or eliminated for non-compliance with these

requirements.

Periodic maintenance fees,

renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO

and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or

applications.

The USPTO and various non-U.S.

governmental patent agencies require compliance with a number

of procedural, documentary, fee payment and other similar provisions during the patent application process.

There are situations

in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete

loss of patent rights in the relevant jurisdiction.

In such an event, our competitors might be able to enter the market and this

circumstance would have a material adverse effect on our business.

is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

If we fail to protect

or enforce our intellectual property rights adequately or secure rights to patents of others, the value of our intellectual property

rights would diminish.

commercial viability will depend in part on obtaining and maintaining patent protection and trade secret protection of our product

candidates, and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges.

Our ability to stop third parties from making, using, selling, offering to sell, or importing our products is dependent upon the

extent to which we obtain rights under valid and enforceable patents or trade secrets that cover these activities.

patent positions of pharmaceutical and biopharmaceutical companies can be highly uncertain and involve complex legal and factual

questions for which important legal principles remain unresolved.

No consistent policy regarding the breadth of claims allowed

in biopharmaceutical patents has emerged to date in the United States.

The biopharmaceutical patent situation outside the United

States is even more uncertain.

Changes in either the patent laws or in interpretations of patent laws in the United States and

other countries may diminish the value of our intellectual property.

Accordingly, we cannot predict the breadth of claims that

may be allowed or enforced in the patents we own.

Further, if any of our patents are deemed invalid and unenforceable, it could

impact our ability to commercialize or license our technology.

degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may

not adequately protect our rights or permit us to gain or keep our competitive advantage.

may be able to make products that are similar to our product candidates but that are not covered by the claims of any patents;

might not have been the first to make the inventions covered by any issued patents or patent applications;

might not have been the first to file patent applications for these inventions;

is possible that any patent applications we own or license will not result in issued patents;

issued patents may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of

legal challenges by third parties;

may not develop additional proprietary technologies that are patentable or protectable under trade secrets law;

patents of others may have an adverse effect on our business.

also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate

or obtainable.

However, trade secrets are difficult to protect.

Although we use reasonable efforts to protect our trade secrets,

our employees, consultants, contractors, outside scientific collaborators, and other advisors may unintentionally or willfully

disclose our information to competitors.

In addition, courts outside the United States are sometimes less willing to protect trade

Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how.

we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties

or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights

that are important to our business.

are party to a research agreement with the Massachusetts Institute of Technology (“MIT”) for development of chimeric

antigen receptor (CAR) technology.

MIT has granted us options to non-exclusively or exclusively license MIT inventions arising

under this research agreement.

We may need to negotiate commercially reasonable terms and conditions with MIT to advance our research

and development activities or allow the commercialization of CAR technology or any other product candidates we may identify and

have a strategic partnership agreement with Assistant Professor Yen-Michael S.

Hsu, M.D., Ph.D.

at Weill Cornell Medical College

of Cornell University (“Weill Cornell”) for co-development of CAR-T, CAR-NK, endothelial cells, stem cells and exosomes.

We have no rights in any Weill Cornell intellectual property resulting from this strategic partnership agreement.

to negotiate terms and conditions with Weill Cornell to advance our research and development activities or allow the commercialization

of technology if this strategic partnership results in Weill Cornell intellectual property.

have an agreement with China Inmunotech for clinical trial work on CD19 under which intellectual property will be co-owned by

us and China Immunotech.

subsidiary Avactis Biosciences, Inc.

and Arbele Limited (“Arbele”) are parties to the joint venture AVAR BioTherapeutics

(“AVAR”) for development of other chimeric antigen receptor (CAR) technology.

Arbele has granted AVAR an exclusive

license to its rights in this technology.

We and AVAR may need to obtain additional licenses from others to advance our research

and development activities or allow the commercialization of CAR technology or any other product candidates we may identify and

agreements with MIT, Dr.

Hsu, and China Immuotech and AVAR’s license agreement with Arbele impose, and we expect that future

agreements will impose, various development, diligence, commercialization, or other obligations on AVAR and us.

In spite of our

efforts, MIT, Dr.

Hsu, China Immuotech or Arbele might conclude that we or AVAR have materially breached its obligations under

such agreements and might therefore terminate the agreements, thereby removing or limiting our ability or our subsidiary AVAR’s

ability to develop and commercialize products and technology covered by these license agreements.

If these in-licenses are terminated,

or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom

to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and

commercialization of CAR technology or other product candidates that we may identify.

Any of the foregoing could have a material

adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

disputes may arise regarding intellectual property subject to a licensing agreement, including:

scope of rights granted under the license agreement and other interpretation-related issues;

extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is

not subject to the licensing agreement;

sublicensing of patent and other rights under our collaborative development relationships;

diligence obligations under the license agreement and what activities satisfy those diligence obligations;

inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by

our licensors and us and our partners;

priority of invention of patented technology.

addition, the agreements under which we currently license intellectual property or technology from third parties are complex,

and certain provisions in such agreements may be susceptible to multiple interpretations.

The resolution of any contract interpretation

disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or

technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which

could have a material adverse effect on our business, financial condition, results of operations, and prospects.

disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements

on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates,

which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

may be subject to claims challenging the inventorship of patents and other intellectual property.

or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest as an inventor

or co-inventor in intellectual property we own or license.

For example, we or our licensors may have inventorship disputes arise

from conflicting obligations of employees, consultants or others who are involved in developing our product candidates.

be subject to claims by third parties asserting that our licensors, employees or we have misappropriated their intellectual property,

or claiming ownership of what we regard as our own intellectual property.

Litigation may be necessary to defend against these

and other claims challenging inventorship or our or our licensors’

ownership of our owned or in-licensed patents, trade

secrets or other intellectual property.

If we or our licensors fail in defending any such claims, in addition to paying monetary

damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property

that is important to our product candidates.

Even if we are successful in defending against such claims, litigation could result

in substantial costs and be a distraction to management and other employees.

Any of the foregoing could have a material adverse

governmental patent agencies require compliance with a number of procedural, documentary,

fee payment and other similar provisions during the patent application process.

There are situations in which non-compliance can

result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the

relevant jurisdiction.

In such an event, our competitors might be able to enter the market and this circumstance would have a material

adverse effect on our business.

It is difficult and costly to protect our

proprietary rights, and we may not be able to ensure their protection.

If we fail to protect or enforce our intellectual property

rights adequately or secure rights to patents of others, the value of our intellectual property rights would diminish.

Our commercial viability

will depend in part on obtaining and maintaining patent protection and trade secret protection of our product candidates, and the

methods used to manufacture them, as well as successfully defending these patents against third-party challenges.

Our ability to

stop third parties from making, using, selling, offering to sell, or importing our products is dependent upon the extent to which

we obtain rights under valid and enforceable patents or trade secrets that cover these activities.

The patent positions of

pharmaceutical and biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which

important legal principles remain unresolved.

No consistent policy regarding the breadth of claims allowed in biopharmaceutical

patents has emerged to date in the United States.

The biopharmaceutical patent situation outside the United States is even more

Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may

diminish the value of our intellectual property.

Accordingly, we cannot predict the breadth of claims that may be allowed or enforced

in the patents we own.

Further, if any of our patents are deemed invalid and unenforceable, it could impact our ability to commercialize

or license our technology.

The degree of future protection

for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights

or permit us to gain or keep our competitive advantage.

others may be able to make products that are similar to our product candidates but that are not covered by the claims of any patents;

we might not have been the first to make the inventions covered by any issued patents or patent applications;

we might not have been the first to file patent applications for these inventions;

it is possible that any patent applications we own or license will not result in issued patents;

any issued patents may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third parties;

we may not develop additional proprietary technologies that are patentable or protectable under trade secrets law;

the patents of others may have an adverse effect on our business.

We also may rely on trade

secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable.

trade secrets are difficult to protect.

Although we use reasonable efforts to protect our trade secrets, our employees, consultants,

contractors, outside scientific collaborators, and other advisors may unintentionally or willfully disclose our information to

In addition, courts outside the United States are sometimes less willing to protect trade secrets.

Moreover, our competitors

may independently develop equivalent knowledge, methods, and know-how.

If we fail to comply with our obligations in the agreements

under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships

with our licensors, we could lose intellectual property rights that are important to our business.

We are party to a research

agreement with the Massachusetts Institute of Technology (“MIT”) for development of chimeric antigen receptor (CAR)

MIT has granted us options to non-exclusively or exclusively license MIT inventions arising under this research agreement.

We may need to negotiate commercially reasonable terms and conditions with MIT to advance our research and development activities

or allow the commercialization of CAR technology or any other product candidates we may identify and pursue.

We have a strategic

partnership agreement with Weill Cornell Medical College of Cornell University (“Weill Cornell”) for co-development

of CAR-T, CAR-NK, endothelial cells, stem cells and exosomes.

We have no rights in any Weill Cornell intellectual property resulting

from this strategic partnership agreement.

We may need to negotiate terms and conditions with Weill Cornell to advance our research

and development activities or allow the commercialization of technology if this strategic partnership results in Weill Cornell

intellectual property.

We have an agreement with

China Inmunotech for clinical trial work on CD19 under which intellectual property will be co-owned by us and China Immunotech.

Our subsidiary Avactis

Biosciences, Inc.

and Arbele Limited (“Arbele”) are parties to the joint venture AVAR BioTherapeutics Ltd.

(“AVAR”)

for development of other chimeric antigen receptor (CAR) technology.

Arbele has granted AVAR an exclusive license to its rights

in this technology.

We and AVAR may need to obtain additional licenses from others to advance our research and development activities

or allow the commercialization of CAR technology or any other product candidates we may identify and pursue.

Our agreements with

MIT, China Immuotech and AVAR’s license agreement with Arbele impose, and we expect that future agreements will impose, various

development, diligence, commercialization, or other obligations on AVAR and us.

In spite of our efforts, MIT, Dr.

Hsu, China Immuotech

or Arbele might conclude that we or AVAR have materially breached its obligations under such agreements and might therefore terminate

the agreements, thereby removing or limiting our ability or our subsidiary AVAR’s ability to develop and commercialize products

and technology covered by these license agreements.

If these in-licenses are terminated, or if the underlying patents fail to provide

the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market,

products identical to ours and we may be required to cease our development and commercialization of CAR technology or other product

candidates that we may identify.

Any of the foregoing could have a material adverse effect on our competitive position, business,

financial conditions, results of operations, and prospects.

Moreover, disputes may

arise regarding intellectual property subject to a licensing agreement, including:

the scope of rights granted under the license agreement and other interpretation-related issues;

the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

the sublicensing of patent and other rights under our collaborative development relationships;

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;

the priority of invention of patented technology.

In addition, the agreements

under which we currently license intellectual property or technology from third parties are complex, and certain provisions in

such agreements may be susceptible to multiple interpretations.

The resolution of any contract interpretation disagreement that

may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase

what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse

effect on our business, financial condition, results of operations, and prospects.

any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and

other proprietary rights would be significantly impaired and our business and competitive position would suffer.

viability also depends upon the skills, knowledge and experience of our scientific and technical personnel, and our consultants

and advisors.

To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to

obtain, we rely on trade secret protection and confidentiality agreements.

To this end, we require all of our employees, consultants,

advisors and contractors to enter into agreements which prohibit unauthorized disclosure and use of confidential information and,

where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to

our business.

These agreements are often limited in duration and may not provide adequate protection for our trade secrets, know-how

or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such

There is no assurance that such agreements will be honored by such parties or enforced in whole or part by the courts.

We cannot be certain that others will not gain access to these trade secrets or that our patents will provide adequate protection.

Others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our

trade secrets.

In addition, enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive

and time consuming, and the outcome is unpredictable.

If any of our trade secrets, know-how or other proprietary information is

improperly disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and

our business and competitive position would suffer.

may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property

rights and we may be unable to protect our rights to, or use of, our technology.

we choose to go to court to stop a third party from using the inventions claimed in our patents, that individual or company has

the right to ask the court to rule that such patents are invalid and/or should not be enforced against that third party.

lawsuits are expensive and would consume time and other resources, even if we were successful in discontinuing the infringement

of our patents.

In addition, there is a risk that the court will decide that these patents are not valid and that we do not have

the right to stop the other party from using the inventions.

There is also the risk that, even if the validity of these patents

is upheld, the court will refuse to stop the other party on the ground that such other party’s activities do not infringe

our rights to these patents.

In addition, the U.S.

Supreme Court has in the past invalidated tests used by the USPTO in granting

patents over the past 20 years.

As a consequence, issued patents may be found to contain invalid claims according to the newly

revised standards.

Some of our own patents may be subject to challenge and subsequent invalidation in a variety of post-grant

proceedings, particularly inter partes review, before the USPTO or during litigation under the revised criteria, which

make it more difficult to defend the validity of claims in already issued patents.

a third party may claim that we or our manufacturing or commercialization partners are using inventions covered by the third party’s

patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling

our product candidates.

These lawsuits are costly and could affect our results of operations and divert the attention of managerial

and technical personnel.

There is a risk that a court could decide that we or our commercialization partners are infringing the

third party’s patents and order us or our partners to stop the activities covered by the patents.

In addition, there is

a risk that a court could order us or our partners to pay the other party damages for having violated the other party’s

The biotechnology industry has produced a proliferation of patents, and it is not always clear to industry participants,

including us, which patents cover various types of products, manufacturing processes or methods of use.

The coverage of patents

is subject to interpretation by the courts, and the interpretation is not always uniform.

If we are sued for patent infringement,

we would need to demonstrate that our products, manufacturing processes or methods of use either do not infringe the patent claims

of the relevant patent and/or that the patent claims are invalid, and we may not be able to do this.

Proving invalidity, in particular,

is difficult since it requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued

some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications

in the United States and many foreign jurisdictions are typically not published until eighteen months after filing, and because

publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed

patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent

the technology.

Our competitors may have filed, and may in the future file, patent applications covering technology similar to

Any such patent applications may have priority over our patent applications or patents, which could further require us to

obtain rights to issued patents covering such technologies.

If another party has filed a United States patent application on inventions

similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention

in the United States.

The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful

if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention,

resulting in a loss of our U.S.

Moreover, if disputes over intellectual property

that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms,

we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse

effect on our business, financial conditions, results of operations, and prospects.

We may be subject to claims challenging

the inventorship of patents and other intellectual property.

We or our licensors may

be subject to claims that former employees, collaborators or other third parties have an interest as an inventor or co-inventor

in intellectual property we own or license.

For example, we or our licensors may have inventorship disputes arise from conflicting

obligations of employees, consultants or others who are involved in developing our product candidates.

We may be subject to claims

by third parties asserting that our licensors, employees or we have misappropriated their intellectual property, or claiming ownership

of what we regard as our own intellectual property.

Litigation may be necessary to defend against these and other claims challenging

inventorship or our or our licensors’

ownership of our owned or in-licensed patents, trade secrets or other intellectual

If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable

intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our

product candidates.

Even if we are successful in defending against such claims, litigation could result in substantial costs and

be a distraction to management and other employees.

Any of the foregoing could have a material adverse effect on our business,

financial condition, results of operations and prospects.

If any of our trade secrets, know-how or

other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly

impaired and our business and competitive position would suffer.

Our viability also depends

upon the skills, knowledge and experience of our scientific and technical personnel, and our consultants and advisors.

protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade

secret protection and confidentiality agreements.

To this end, we require all of our employees, consultants, advisors and contractors

to enter into agreements which prohibit unauthorized disclosure and use of confidential information and, where applicable, require

disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.

These agreements

are often limited in duration and may not provide adequate protection for our trade secrets, know-how or other proprietary information

in the event of any unauthorized use or disclosure or the lawful development by others of such information.

There is no assurance

that such agreements will be honored by such parties or enforced in whole or part by the courts.

We cannot be certain that others

will not gain access to these trade secrets or that our patents will provide adequate protection.

Others may independently develop

substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets.

In addition, enforcing

a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome

is unpredictable.

If any of our trade secrets, know-how or other proprietary information is improperly disclosed, the value of

our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position

would suffer.

We may incur substantial costs as a result

of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our

rights to, or use of, our technology.

If we choose to go to court

to stop a third party from using the inventions claimed in our patents, that individual or company has the right to ask the court

to rule that such patents are invalid and/or should not be enforced against that third party.

These lawsuits are expensive and

would consume time and other resources, even if we were successful in discontinuing the infringement of our patents.

there is a risk that the court will decide that these patents are not valid and that we do not have the right to stop the other

party from using the inventions.

There is also the risk that, even if the validity of these patents is upheld, the court will refuse

to stop the other party on the ground that such other party’s activities do not infringe our rights to these patents.

addition, the U.S.

Supreme Court has in the past invalidated tests used by the USPTO in granting patents over the past 20 years.

As a consequence, issued patents may be found to contain invalid claims according to the newly revised standards.

Some of our own

patents may be subject to challenge and subsequent invalidation in a variety of post-grant proceedings, particularly inter partes

review, before the USPTO or during litigation under the revised criteria, which make it more difficult to defend the validity of

claims in already issued patents.

Furthermore, a third party

may claim that we or our manufacturing or commercialization partners are using inventions covered by the third party’s patent

rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product

These lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical

There is a risk that a court could decide that we or our commercialization partners are infringing the third party’s

patents and order us or our partners to stop the activities covered by the patents.

In addition, there is a risk that a court could

order us or our partners to pay the other party damages for having violated the other party’s patents.

The biotechnology

industry has produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents

cover various types of products, manufacturing processes or methods of use.

The coverage of patents is subject to interpretation

by the courts, and the interpretation is not always uniform.

If we are sued for patent infringement, we would need to demonstrate

that our products, manufacturing processes or methods of use either do not infringe the patent claims of the relevant patent and/or

that the patent claims are invalid, and we may not be able to do this.

Proving invalidity, in particular, is difficult since it

requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.

As some patent applications

in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States

and many foreign jurisdictions are typically not published until eighteen months after filing, and because publications in the

scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications

for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology.

competitors may have filed, and may in the future file, patent applications covering technology similar to ours.

Any such patent

applications may have priority over our patent applications or patents, which could further require us to obtain rights to issued

patents covering such technologies.

If another party has filed a United States patent application on inventions similar to ours,

we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United

The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst

to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss

patent position with respect to such inventions.

of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have

substantially greater resources.

In addition, any uncertainties resulting from the initiation and continuation of any litigation

or inter partes review proceedings could have a material adverse effect on our ability to raise the funds necessary to

continue our operations.

jurisdictions in which we operate have enacted legislation which allows members of the public to access information under statutes

similar to the U.S.

Some of our competitors

may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater

In addition, any uncertainties resulting from the initiation and continuation of any litigation or inter partes

review proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

Some jurisdictions in which

we operate have enacted legislation which allows members of the public to access information under statutes similar to the U.S.

Freedom of Information Act.

Even though we believe our information would be excluded from the scope of such

statutes, there are no assurances that we can protect our confidential information from being disclosed under the provisions of

If any confidential or proprietary information is released to the public, such disclosures may negatively impact our

ability to protect our intellectual property rights.

or compromises of our information security systems or our information technology systems or infrastructure could result in exposure

of private information, disruption of our business and damage to our reputation, which could harm our business, results of operation

and financial condition.

utilize information security and information technology systems and websites that allow for the secure storage and transmission

of proprietary or private information regarding our clients, patients, employees, vendors and others, including individually identifiable

health information.

A security breach of our network, hosted service providers, or vendor systems, may expose us to a risk of

loss or misuse of this information, litigation and potential liability.

Hackers and data thieves are increasingly sophisticated

and operate large-scale and complex automated attacks, including on companies within the healthcare industry.

Although we believe

that we take appropriate measures to safeguard sensitive information within our possession, we may not have the resources or technical

sophistication to anticipate or prevent rapidly-evolving types of cyber-attacks targeted at us, our clients, our patients, or

others who have entrusted us with information.

Actual or anticipated attacks may cause us to incur costs, including costs to deploy

additional personnel and protection technologies, train employees, and engage third-party experts and consultants.

industry standard security technology to protect personal information.

Advances in computer capabilities, new technological discoveries,

or other developments may result in the technology used by us to protect personal information or other data being breached or

To our knowledge, we have not experienced any material breach of our cybersecurity systems.

If our or our third-party

service provider systems fail to operate effectively or are damaged, destroyed, or shut down, or there are problems with transitioning

to upgraded or replacement systems, or there are security breaches in these systems, any of the aforementioned could occur as

a result of natural disasters, software or equipment failures, telecommunications failures, loss or theft of equipment, acts of

terrorism, circumvention of security systems, or other cyber-attacks, we could experience delays or decreases in revenue, and

reduced efficiency of our operations.

Additionally, any of these events could lead to violations of privacy laws, loss of customers,

or loss, misappropriation or corruption of confidential information, trade secrets or data, which could expose us to potential

litigation, regulatory actions, sanctions or other statutory penalties, any or all of which could adversely affect our business,

and cause us to incur significant losses and remediation costs.

be exposed to liabilities under the Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt

Practices Act or Chinese anti-corruption law could have a material adverse effect on our business.

are subject to the Foreign Corrupt Practice Act, or FCPA, and other laws that prohibit improper payments or offers of payments

to foreign governments and their officials and political parties by U.S.

persons and issuers as defined by the statute for the

purpose of obtaining or retaining business.

Even though we believe our information would be excluded from the scope of such statutes, there are

no assurances that we can protect our confidential information from being disclosed under the provisions of such laws.

If any confidential

or proprietary information is released to the public, such disclosures may negatively impact our ability to protect our intellectual

property rights.

Breaches or compromises of our information

security systems or our information technology systems or infrastructure could result in exposure of private information, disruption

of our business and damage to our reputation, which could harm our business, results of operation and financial condition.

We utilize information

security and information technology systems and websites that allow for the secure storage and transmission of proprietary or private

information regarding our clients, patients, employees, vendors and others, including individually identifiable health information.

A security breach of our network, hosted service providers, or vendor systems, may expose us to a risk of loss or misuse of this

information, litigation and potential liability.

Hackers and data thieves are increasingly sophisticated and operate large-scale

and complex automated attacks, including on companies within the healthcare industry.

Although we believe that we take appropriate

measures to safeguard sensitive information within our possession, we may not have the resources or technical sophistication to

anticipate or prevent rapidly-evolving types of cyber-attacks targeted at us, our clients, our patients, or others who have entrusted

us with information.

Actual or anticipated attacks may cause us to incur costs, including costs to deploy additional personnel

and protection technologies, train employees, and engage third-party experts and consultants.

We invest in industry standard security

technology to protect personal information.

Advances in computer capabilities, new technological discoveries, or other developments

may result in the technology used by us to protect personal information or other data being breached or compromised.

To our knowledge,

we have not experienced any material breach of our cybersecurity systems.

If our or our third-party service provider systems fail

to operate effectively or are damaged, destroyed, or shut down, or there are problems with transitioning to upgraded or replacement

systems, or there are security breaches in these systems, any of the aforementioned could occur as a result of natural disasters,

software or equipment failures, telecommunications failures, loss or theft of equipment, acts of terrorism, circumvention of security

systems, or other cyber-attacks, we could experience delays or decreases in revenue, and reduced efficiency of our operations.

Additionally, any of these events could lead to violations of privacy laws, loss of customers, or loss, misappropriation or corruption

of confidential information, trade secrets or data, which could expose us to potential litigation, regulatory actions, sanctions

or other statutory penalties, any or all of which could adversely affect our business, and cause us to incur significant losses

and remediation costs.

We may be exposed to liabilities under the

Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act or Chinese anti-corruption

law could have a material adverse effect on our business.

We are subject to the Foreign

Corrupt Practice Act, or FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments and

their officials and political parties by U.S.

persons and issuers as defined by the statute for the purpose of obtaining or retaining

Chinese anti-corruption law also strictly prohibits bribery of government officials.

We have operations, agreements with third parties and make sales in China, where corruption may occur.

Our activities in China

create the risk of unauthorized payments or offers of payments by one of the employees, consultants, sales agents or distributors

of our company, even though these parties are not always subject to our control.

It is our policy to implement safeguards to prevent

these practices by our employees.

However, our existing safeguards and any future improvements may prove to be less than effective,

and the employees, consultants, sales agents or distributors of our company may engage in conduct for which we might be held responsible.

of the FCPA or other anti-corruption laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities,

which could negatively affect our business, operating results and financial condition.

In addition, the United States government

may seek to hold our company liable for successor liability FCPA violations committed by companies in which we invest or that

Risk Factors Related to Clinical

and Commercialization Activity

not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to do so,

the FDA may not permit us to proceed.

has initiated its first-in-human clinical trial of CD19 CAR-T candidate, AVA-001 in August 2019 at the Hebei Yanda Lu Daopei Hospital

and Beijing Lu Daopei Hospital in China (the world’s single largest CAR-T treatment network with over 600 patients being

treated with CAR-T) for the indication of relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin Lymphoma.

hope to file a number of investigational new drug applications, or INDs, for cell based therapies and diagnostic systems through

INDs over the next several years.

However, the timing of our filing of these INDs is primarily dependent on receiving further

data from our pre-clinical studies, and our timing of filing on all product candidates is subject to further research.

Additionally,

our submission of INDs is contingent upon having sufficient financial resources to prepare and complete the application.

cannot be sure that submission of an IND will result in the United States Food and Drug Administration, or FDA, allowing further

clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical

Any IND we submit could be denied by the FDA or the FDA could place any future investigation of ours on clinical hold

until we provide additional information, either before or after clinical trials are initiated.

Additionally, even if such regulatory

authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application,

we cannot guarantee that such regulatory authorities will not change their requirements in the future.

Unfavorable future trial

results or other factors, such as insufficient capital to continue development of a product candidate or program, could also cause

us to voluntarily withdraw an effective IND.

limited experience in conducting clinical trials.

have limited human clinical trial experience with respect to our product candidates.

We have operations, agreements with

third parties and make sales in China, where corruption may occur.

Our activities in China create the risk of unauthorized payments

or offers of payments by one of the employees, consultants, sales agents or distributors of our company, even though these parties

are not always subject to our control.

It is our policy to implement safeguards to prevent these practices by our employees.

our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants, sales

agents or distributors of our company may engage in conduct for which we might be held responsible.

Violations of the FCPA

or other anti-corruption laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which

could negatively affect our business, operating results and financial condition.

In addition, the United States government may

seek to hold our company liable for successor liability FCPA violations committed by companies in which we invest or that we acquire.

Risk Factors Related to Clinical and Commercialization Activity

We may not be able to file INDs to commence

additional clinical trials on the timelines we expect, and even if we are able to do so, the FDA may not permit us to proceed.

Avalon has initiated its

first-in-human clinical trial of CD19 CAR-T candidate, AVA-001 in August 2019 at the Hebei Yanda Lu Daopei Hospital and Beijing

Lu Daopei Hospital in China (the world’s single largest CAR-T treatment network with over 600 patients being treated with

CAR-T) for the indication of relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin Lymphoma.

We hope to file

a number of investigational new drug applications, or INDs, for cell based therapies and diagnostic systems through INDs over the

next several years.

However, the timing of our filing of these INDs is primarily dependent on receiving further data from our pre-clinical

studies, and our timing of filing on all product candidates is subject to further research.

Additionally, our submission of INDs

is contingent upon having sufficient financial resources to prepare and complete the application.

We cannot be sure that

submission of an IND will result in the United States Food and Drug Administration, or FDA, allowing further clinical trials to

begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical trials.

we submit could be denied by the FDA or the FDA could place any future investigation of ours on clinical hold until we provide

additional information, either before or after clinical trials are initiated.

Additionally, even if such regulatory authorities

agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee

that such regulatory authorities will not change their requirements in the future.

Unfavorable future trial results or other factors,

such as insufficient capital to continue development of a product candidate or program, could also cause us to voluntarily withdraw

an effective IND.

We have limited experience in conducting

clinical trials.

We have limited human

clinical trial experience with respect to our product candidates.

Although our CEO, Dr.

David Jin, is formerly

with the FDA, this will not provide assurance of success.

The clinical testing process is governed by stringent regulation and

is highly complex, costly, time-consuming, and uncertain as to outcome, and pharmaceutical products and products used in the regeneration

of tissue may invite particularly close scrutiny and requirements from the FDA and other regulatory bodies.

Our failure or the

failure of our collaborators to conduct human clinical trials successfully or our failure to capitalize on the results of human

clinical trials for our product candidates would have a material adverse effect on us.

David Jin, is formerly with the FDA, this

will not provide assurance of success.

The clinical testing process is governed by stringent regulation and is highly complex,

costly, time-consuming, and uncertain as to outcome, and pharmaceutical products and products used in the regeneration of tissue

may invite particularly close scrutiny and requirements from the FDA and other regulatory bodies.

Our failure or the failure of

our collaborators to conduct human clinical trials successfully or our failure to capitalize on the results of human clinical

trials for our product candidates would have a material adverse effect on us.

If our clinical trials of our product candidates

1 unchanged sentence

States or elsewhere, or if they show undesirable side effects, we will be unable to commercialize these product candidates.

receive regulatory approval for the commercial sale of our product candidates, we must conduct adequate and well-controlled clinical

trials to demonstrate efficacy and safety in humans.

To receive regulatory approval

for the commercial sale of our product candidates, we must conduct adequate and well-controlled clinical trials to demonstrate

efficacy and safety in humans.

Clinical failure can occur at any stage of the testing.

Our clinical trials

may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical

and/or non-clinical testing.

In addition, the results of our clinical trials may show that our product candidates are ineffective

or may cause undesirable side effects, which could interrupt, delay or halt clinical trials, resulting in the denial of regulatory

approval by the FDA and other regulatory authorities.

Our clinical trials may produce negative

or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or non-clinical testing.

In addition, the results of our clinical trials may show that our product candidates are ineffective or may cause undesirable side

effects, which could interrupt, delay or halt clinical trials, resulting in the denial of regulatory approval by the FDA and other

regulatory authorities.

In addition, negative, delayed or inconclusive results may result in:

withdrawal of clinical trial participants;

the termination

of clinical trial sites or entire trial programs;

costs of related

substantial monetary

awards to patients or other claimants;

impairment of our

business reputation;

the withdrawal of clinical trial participants;

the termination of clinical trial sites or entire trial programs;

costs of related litigation;

substantial monetary awards to patients or other claimants;

impairment of our business reputation;

loss of revenues;

the inability to

commercialize our product candidates.

in the commencement, enrollment, and completion of clinical testing could result in increased costs to us and delay or limit our

ability to obtain regulatory approval for our product candidates.

in the commencement, enrollment or completion of clinical testing could significantly affect our product development costs.

clinical trial may be suspended or terminated by us, the FDA, or other regulatory authorities due to a number of factors.

commencement and completion of clinical trials require us to identify and maintain a sufficient number of trial sites, many of

which may already be engaged in other clinical trial programs for the same indication as our product candidates.

We may be required

to withdraw from a clinical trial as a result of changing standards of care, or we may become ineligible to participate in clinical

We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all.

The commencement,

enrollment and completion of clinical trials can be delayed for a number of reasons, including, but not limited to, delays related

findings in pre-clinical

reaching agreements

on acceptable terms with prospective clinical research organizations, or CROs, and trial sites, the terms of which can be

subject to extensive negotiation and may vary significantly among different CROs and trial sites;

obtaining regulatory

approval to commence a clinical trial;

complying with conditions

imposed by a regulatory authority regarding the scope or term of a clinical trial, or being required to conduct additional

trials before moving on to the next phase of trials;

obtaining institutional

review board, or IRB, approval to conduct a clinical trial at numerous prospective sites;

recruiting and enrolling

patients to participate in clinical trials for a variety of reasons, including the size of the patient population, nature

of trial protocol, meeting the enrollment criteria for our studies, screening failures, the inability of the sites to conduct

trial procedures properly, the availability of approved effective treatments for the relevant disease and competition from

other clinical trial programs for similar indications;

retaining patients

who have initiated their participation in a clinical trial but may be prone to withdraw due to the treatment protocol, lack

of efficacy, personal issues, or side effects from the therapy, or who are lost to further follow-up;

manufacturing sufficient

quantities of a product candidate for use in clinical trials on a timely basis;

complying with design

protocols of any applicable special protocol assessment we receive from the FDA;

severe or unexpected

cell therapy side effects experienced by patients in a clinical trial;

collecting, analyzing

and reporting final data from the clinical trials;

breaches in quality

of manufacturing runs that compromise all or some of the doses made;

the inability to commercialize our product candidates.

Delays in the commencement, enrollment,

and completion of clinical testing could result in increased costs to us and delay or limit our ability to obtain regulatory approval

for our product candidates.

Delays in the commencement,

enrollment or completion of clinical testing could significantly affect our product development costs.

A clinical trial may be

suspended or terminated by us, the FDA, or other regulatory authorities due to a number of factors.

The commencement and completion

of clinical trials require us to identify and maintain a sufficient number of trial sites, many of which may already be engaged

in other clinical trial programs for the same indication as our product candidates.

We may be required to withdraw from a clinical

trial as a result of changing standards of care, or we may become ineligible to participate in clinical studies.

We do not know

whether planned clinical trials will begin on time or be completed on schedule, if at all.

The commencement, enrollment and completion

of clinical trials can be delayed for a number of reasons, including, but not limited to, delays related to:

findings in pre-clinical studies;

reaching agreements on acceptable terms with prospective clinical research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

obtaining regulatory approval to commence a clinical trial;

complying with conditions imposed by a regulatory authority regarding the scope or term of a clinical trial, or being required to conduct additional trials before moving on to the next phase of trials;

obtaining institutional review board, or IRB, approval to conduct a clinical trial at numerous prospective sites;

recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including the size of the patient population, nature of trial protocol, meeting the enrollment criteria for our studies, screening failures, the inability of the sites to conduct trial procedures properly, the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications;

retaining patients who have initiated their participation in a clinical trial but may be prone to withdraw due to the treatment protocol, lack of efficacy, personal issues, or side effects from the therapy, or who are lost to further follow-up;

manufacturing sufficient quantities of a product candidate for use in clinical trials on a timely basis;

complying with design protocols of any applicable special protocol assessment we receive from the FDA;

severe or unexpected cell therapy side effects experienced by patients in a clinical trial;

collecting, analyzing and reporting final data from the clinical trials;

breaches in quality of manufacturing runs that compromise all or some of the doses made;

positive results in FDA-required viral testing;

abnormalities in our cell product;

or contamination in our manufacturing facilities, all of which events would necessitate

disposal of all cells made from that source;

availability of

materials provided by third parties necessary to manufacture our product candidates;

availability of

adequate amounts of acceptable tissue for preparation of master cell banks for our products;

requirements to

conduct additional trials and studies, and increased expenses associated with the services of our CROs and other third parties.

we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently

contemplate, we or our development partners, if any, may be delayed in obtaining, or may not be able to obtain or maintain, clinical

or marketing approval for these product candidates.

We may not be able to obtain approval for indications that are as broad as

intended, or we may be able to obtain approval only for indications that are entirely different from those indications for which

we sought approval.

in regulatory requirements and guidance may occur, and we may need to amend clinical trial protocols to reflect these changes

with appropriate regulatory authorities.

Amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination,

which may impact the costs, timing, or successful completion of a clinical trial.

If we experience delays in the completion of,

or if we terminate, our clinical trials, the commercial prospects for our product candidates will be harmed, and our ability to

generate product revenues will be delayed.

In addition, many of the factors that cause, or lead to, a delay in the commencement

or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.

we are able to ultimately commercialize our product candidates, other therapies for the same or similar indications may have been

introduced to the market and already established a competitive advantage.

karyotypic abnormalities in our cell product;

or contamination in our manufacturing facilities, all of which events would necessitate disposal of all cells made from that source;

availability of materials provided by third parties necessary to manufacture our product candidates;

availability of adequate amounts of acceptable tissue for preparation of master cell banks for our products;

requirements to conduct additional trials and studies, and increased expenses associated with the services of our CROs and other third parties.

If we are required to conduct

additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, we or our development

partners, if any, may be delayed in obtaining, or may not be able to obtain or maintain, clinical or marketing approval for these

product candidates.

We may not be able to obtain approval for indications that are as broad as intended, or we may be able to obtain

approval only for indications that are entirely different from those indications for which we sought approval.

Changes in regulatory requirements

and guidance may occur, and we may need to amend clinical trial protocols to reflect these changes with appropriate regulatory

Amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may impact the

costs, timing, or successful completion of a clinical trial.

If we experience delays in the completion of, or if we terminate,

our clinical trials, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenues

will be delayed.

In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical

trials may also ultimately lead to the denial of regulatory approval of a product candidate.

Even if we are able to ultimately

commercialize our product candidates, other therapies for the same or similar indications may have been introduced to the market

and already established a competitive advantage.

Any delays in obtaining regulatory approvals may:

delay commercialization

of, and our ability to derive product revenues from, our product candidates;

impose costly procedures

diminish any competitive

advantages that we may otherwise enjoy.

depends upon the viability of our product candidates and we cannot be certain any of them will receive regulatory approval to

be commercialized.

will need FDA approval to market and sell any of our product candidates in the United States and approvals from FDA-equivalent

regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions.

In order to obtain

FDA approval of any of our product candidates, we must submit to the FDA a new drug application, or NDA, or a biologics license

application, or BLA, demonstrating that the product candidate is safe for humans and effective for its intended use.

This demonstration

requires significant research and animal tests, which are referred to as pre-clinical studies, as well as human tests, which are

referred to as clinical trials.

Satisfaction of the FDA’s regulatory requirements typically takes many years, depends upon

the type, complexity, and novelty of the product candidate, and requires substantial resources for research, development, testing

and manufacturing.

We cannot predict whether our research and clinical approaches will result in cell therapies that the FDA considers

safe for humans and effective for indicated uses.

The FDA has substantial discretion in the drug approval process and may require

us to conduct additional pre-clinical and clinical testing or to perform post-marketing studies.

The approval process may also

be delayed by changes in government regulation, future legislation, administrative action or changes in FDA policy that occur

prior to or during our regulatory review.

if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs or BLAs, as applicable.

sure that we will ever obtain regulatory clearance for our product candidates.

Failure to obtain FDA approval of any of our product

candidates will reduce our number of potentially salable products and, therefore, corresponding product revenues, and will have

a material and adverse impact on our business.

results of earlier pre-clinical studies or clinical trials are not necessarily predictive of future results, any product candidate

we advance into clinical trials may not have favorable results in later clinical trials or receive regulatory approval.

if our pre-clinical studies and clinical trials are completed as planned, clinical trials, we cannot be certain that their results

will support the claims of our product candidates.

Positive results in pre-clinical testing and early clinical trials do not ensure

that results from later clinical trials will also be positive, and we cannot be sure that the results of later clinical trials

will replicate the results of prior clinical trials and pre-clinical testing.

A number of companies in the pharmaceutical industry,

including those with greater resources and experience, have suffered significant setbacks in Phase II or Phase III clinical trials,

even after seeing promising results in earlier clinical trials.

clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses.

This failure would cause us to abandon a product candidate and may delay development of other product candidates.

Any delay in,

or termination of, our clinical trials will delay or cause us to refrain from the filing of our NDAs and/or BLAs with the FDA

and, ultimately, our ability to commercialize our product candidates and generate product revenues.

In addition, our clinical

trials to date involve small patient populations.

Because of the small sample size, the results of these clinical trials may not

be indicative of future results.

faces significant government regulation, and there is no guarantee that our product candidates will receive regulatory approval.

research and development activities, pre-clinical studies, anticipated human clinical trials, and anticipated manufacturing and

marketing of our potential products are subject to extensive regulation by the FDA and other regulatory authorities in the United

States, as well as by regulatory authorities in other countries.

In the United States, our product candidates are subject to regulation

as biological products or as combination biological products/medical devices under the Federal Food, Drug and Cosmetic Act, the

Public Health Service Act and other statutes, as outlined in the Code of Federal Regulations.

Different regulatory requirements

may apply to our products depending on how they are categorized by the FDA under these laws.

These regulations can be subject

to substantial and significant interpretation, addition, amendment or revision by the FDA and by the legislative process.

FDA may determine that we will need to undertake clinical trials beyond those currently planned.

Furthermore, the FDA may determine

that results of clinical trials do not support approval for the product.

Similar determinations may be encountered in foreign

The FDA will continue to monitor products in the market after approval, if any, and may determine to withdraw its approval

or otherwise seriously affect the marketing efforts for any such product.

The same possibilities exist for trials to be conducted

outside of the United States that are subject to regulations established by local authorities and local law.

Any such determinations

would delay or deny the introduction of our product candidates to the market and have a material adverse effect on our business,

financial condition, and results of operations.

based therapeutics are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Agency, other federal

agencies and corresponding state agencies to ensure strict compliance with good manufacturing practices, and other government

regulations and corresponding foreign standards.

delay commercialization of, and our ability to derive product revenues from, our product candidates;

impose costly procedures on us;

diminish any competitive advantages that we may otherwise enjoy.

Our success depends upon the viability of

our product candidates and we cannot be certain any of them will receive regulatory approval to be commercialized.

We will need FDA approval

to market and sell any of our product candidates in the United States and approvals from FDA-equivalent regulatory authorities

in foreign jurisdictions to commercialize our product candidates in those jurisdictions.

In order to obtain FDA approval of any

of our product candidates, we must submit to the FDA a new drug application, or NDA, or a biologics license application, or BLA,

demonstrating that the product candidate is safe for humans and effective for its intended use.

This demonstration requires significant

research and animal tests, which are referred to as pre-clinical studies, as well as human tests, which are referred to as clinical

Satisfaction of the FDA’s regulatory requirements typically takes many years, depends upon the type, complexity,

and novelty of the product candidate, and requires substantial resources for research, development, testing and manufacturing.

We cannot predict whether our research and clinical approaches will result in cell therapies that the FDA considers safe for humans

and effective for indicated uses.

The FDA has substantial discretion in the drug approval process and may require us to conduct

additional pre-clinical and clinical testing or to perform post-marketing studies.

The approval process may also be delayed by

changes in government regulation, future legislation, administrative action or changes in FDA policy that occur prior to or during

our regulatory review.

Even if we comply with

all FDA requests, the FDA may ultimately reject one or more of our NDAs or BLAs, as applicable.

We cannot be sure that we will

ever obtain regulatory clearance for our product candidates.

Failure to obtain FDA approval of any of our product candidates will

reduce our number of potentially salable products and, therefore, corresponding product revenues, and will have a material and

adverse impact on our business.

As the results of earlier pre-clinical studies

or clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may

not have favorable results in later clinical trials or receive regulatory approval.

Even if our pre-clinical

studies and clinical trials are completed as planned, clinical trials, we cannot be certain that their results will support the

claims of our product candidates.

Positive results in pre-clinical testing and early clinical trials do not ensure that results

from later clinical trials will also be positive, and we cannot be sure that the results of later clinical trials will replicate

the results of prior clinical trials and pre-clinical testing.

A number of companies in the pharmaceutical industry, including

those with greater resources and experience, have suffered significant setbacks in Phase II or Phase III clinical trials, even

after seeing promising results in earlier clinical trials.

Our clinical trial process

may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses.

This failure would cause

us to abandon a product candidate and may delay development of other product candidates.

Any delay in, or termination of, our clinical

trials will delay or cause us to refrain from the filing of our NDAs and/or BLAs with the FDA and, ultimately, our ability to commercialize

our product candidates and generate product revenues.

In addition, our clinical trials to date involve small patient populations.

Because of the small sample size, the results of these clinical trials may not be indicative of future results.

Our business faces significant government

regulation, and there is no guarantee that our product candidates will receive regulatory approval.

Our research and development

activities, pre-clinical studies, anticipated human clinical trials, and anticipated manufacturing and marketing of our potential

products are subject to extensive regulation by the FDA and other regulatory authorities in the United States, as well as by regulatory

authorities in other countries.

In the United States, our product candidates are subject to regulation as biological products

or as combination biological products/medical devices under the Federal Food, Drug and Cosmetic Act, the Public Health Service

Act and other statutes, as outlined in the Code of Federal Regulations.

Different regulatory requirements may apply to our products

depending on how they are categorized by the FDA under these laws.

These regulations can be subject to substantial and significant

interpretation, addition, amendment or revision by the FDA and by the legislative process.

The FDA may determine that we will

need to undertake clinical trials beyond those currently planned.

Furthermore, the FDA may determine that results of clinical

trials do not support approval for the product.

Similar determinations may be encountered in foreign countries.

The FDA will continue

to monitor products in the market after approval, if any, and may determine to withdraw its approval or otherwise seriously affect

the marketing efforts for any such product.

The same possibilities exist for trials to be conducted outside of the United States

that are subject to regulations established by local authorities and local law.

Any such determinations would delay or deny the

introduction of our product candidates to the market and have a material adverse effect on our business, financial condition,

and results of operations.

Cell based therapeutics

are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Agency, other federal agencies and corresponding

state agencies to ensure strict compliance with good manufacturing practices, and other government regulations and corresponding

foreign standards.

We do not have control over third-party manufacturers’

compliance with

these regulations and standards, nor can we guarantee that we will maintain compliance with such regulations in regards to our

own manufacturing processes.

Other risks include:

regulatory authorities

may require the addition of labeling statements, specific warnings, a contraindication, or field alerts to physicians and

regulatory authorities

may withdraw their approval of the IND or the product or require us to take our approved products off the market;

we may be required

to change the way the product is manufactured or administered and we may be required to conduct additional clinical trials

or change the labeling of our products;

we may have limitations

on how we promote our products;

we may be subject

to litigation or product liability claims.

if our product candidates receive regulatory approval in the United States, we may never receive approval or commercialize our

product candidates outside of the United States.

In order to market and commercialize any product candidate outside of the United

States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding manufacturing,

safety and efficacy.

Approval procedures vary among countries and can involve additional product testing and additional administrative

review periods.

The time required to obtain approval in other countries might differ from that required to obtain FDA approval.

The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United

States as well as other risks.

Regulatory approval in one country does not ensure regulatory approval in another, but a failure

or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others.

Failure to obtain regulatory approval in other countries, or any delay or setback in obtaining such approval, could have the same

adverse effects detailed above regarding FDA approval in the United States.

Such effects include the risks that our product candidates

may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect

on product sales and potential royalties, and that such approval may be subject to limitations on the indicated uses for which

the product may be marketed or require costly, post-marketing follow-up studies.

if our product candidates receive regulatory approval, we may still face future development and regulatory difficulties.

regulatory approval is obtained, the FDA may still impose significant restrictions on a product’s indicated uses

or marketing, or impose ongoing requirements for potentially costly post-approval studies.

If any of our products were granted

accelerated approval, FDA could require post-marketing confirmatory trials to verify and describe the anticipated effect on irreversible

morbidity or mortality or other clinical benefit.

FDA may withdraw approval of a drug or indication approved under the accelerated

approval pathway if a trial required to verify the predicted clinical benefit of the product fails to verify such benefit;

evidence demonstrates that the product is not shown to be safe or effective under the conditions of use;

the applicant fails to

conduct any required post-approval trial of the drug with due diligence;

or the applicant disseminates false or misleading promotional

materials relating to the product.

In addition, the FDA currently requires as a condition for accelerated approval the pre-approval

of promotional materials, which could adversely impact the timing of the commercial launch of the product.

the number of recent high-profile adverse safety events with certain drug and cell related products, the FDA may require, as a

condition of approval, costly risk management programs, which may include safety surveillance, restricted distribution and use,

patient education, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval

of promotional materials, and restrictions on direct-to-consumer advertising.

Furthermore, heightened Congressional scrutiny on

the adequacy of the FDA’s drug approval process and the FDA’s efforts to assure the safety of marketed cell based

therapy has resulted in the proposal of new legislation addressing drug safety issues.

If enacted, any new legislation could result

in delays or increased costs during the period of product development, clinical trials, and regulatory review and approval, as

well as increased costs to assure compliance with any new post-approval regulatory requirements.

Any of these restrictions or

requirements could force us to conduct costly studies or increase the time for us to become profitable.

For example, any labeling

approved for any of our product candidates may include a restriction on the term of its use, or it may not include one or more

of our intended indications.

product candidates will also be subject to ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion,

record-keeping, and submission of safety and other post-market information on the cell based therapy.

New issues may arise during

a product lifecycle that did not exist, or were unknown, at the time of product approval, such as adverse events of unanticipated

severity or frequency, or problems with the facility where the product is manufactured.

Since approved products, manufacturers,

and manufacturers’

facilities are subject to continuous review and periodic inspections, these new issues post-approval

may result in voluntary actions by us or may result in a regulatory agency imposing restrictions on that product or us, including

requiring withdrawal of the product from the market or for use in a clinical study.

If our product candidates fail to comply with

applicable regulatory requirements, such as good manufacturing practices, a regulatory agency may:

compliance with these regulations and standards,

nor can we guarantee that we will maintain compliance with such regulations in regards to our own manufacturing processes.

risks include:

regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication, or field alerts to physicians and pharmacies;

regulatory authorities may withdraw their approval of the IND or the product or require us to take our approved products off the market;

we may be required to change the way the product is manufactured or administered and we may be required to conduct additional clinical trials or change the labeling of our products;

we may have limitations on how we promote our products;

we may be subject to litigation or product liability claims.

Even if our product candidates

receive regulatory approval in the United States, we may never receive approval or commercialize our product candidates outside

of the United States.

In order to market and commercialize any product candidate outside of the United States, we must establish

and comply with numerous and varying regulatory requirements of other countries regarding manufacturing, safety and efficacy.

procedures vary among countries and can involve additional product testing and additional administrative review periods.

required to obtain approval in other countries might differ from that required to obtain FDA approval.

The regulatory approval

process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other

Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory

approval in one country may have a negative effect on the regulatory approval process in others.

Failure to obtain regulatory approval

in other countries, or any delay or setback in obtaining such approval, could have the same adverse effects detailed above regarding

FDA approval in the United States.

Such effects include the risks that our product candidates may not be approved for all indications

requested, which could limit the uses of our product candidates and have an adverse effect on product sales and potential royalties,

and that such approval may be subject to limitations on the indicated uses for which the product may be marketed or require costly,

post-marketing follow-up studies.

Even if our product candidates receive regulatory

approval, we may still face future development and regulatory difficulties.

approval is obtained, the FDA may still impose significant restrictions on a product’s indicated uses or marketing, or impose

ongoing requirements for potentially costly post-approval studies.

If any of our products were granted accelerated approval, FDA

could require post-marketing confirmatory trials to verify and describe the anticipated effect on irreversible morbidity or mortality

or other clinical benefit.

FDA may withdraw approval of a drug or indication approved under the accelerated approval pathway if

a trial required to verify the predicted clinical benefit of the product fails to verify such benefit;

other evidence demonstrates

that the product is not shown to be safe or effective under the conditions of use;

the applicant fails to conduct any required

post-approval trial of the drug with due diligence;

or the applicant disseminates false or misleading promotional materials relating

to the product.

In addition, the FDA currently requires as a condition for accelerated approval the pre-approval of promotional

materials, which could adversely impact the timing of the commercial launch of the product.

Given the number of recent

high-profile adverse safety events with certain drug and cell related products, the FDA may require, as a condition of approval,

costly risk management programs, which may include safety surveillance, restricted distribution and use, patient education, enhanced

labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials,

and restrictions on direct-to-consumer advertising.

Furthermore, heightened Congressional scrutiny on the adequacy of the FDA’s

drug approval process and the FDA’s efforts to assure the safety of marketed cell based therapy has resulted in the proposal

of new legislation addressing drug safety issues.

If enacted, any new legislation could result in delays or increased costs during

the period of product development, clinical trials, and regulatory review and approval, as well as increased costs to assure compliance

with any new post-approval regulatory requirements.

Any of these restrictions or requirements could force us to conduct costly

studies or increase the time for us to become profitable.

For example, any labeling approved for any of our product candidates

may include a restriction on the term of its use, or it may not include one or more of our intended indications.

Our product candidates

will also be subject to ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion, record-keeping,

and submission of safety and other post-market information on the cell based therapy.

New issues may arise during a product lifecycle

that did not exist, or were unknown, at the time of product approval, such as adverse events of unanticipated severity or frequency,

or problems with the facility where the product is manufactured.

Since approved products, manufacturers, and manufacturers’

facilities are subject to continuous review and periodic inspections, these new issues post-approval may result in voluntary actions

by us or may result in a regulatory agency imposing restrictions on that product or us, including requiring withdrawal of the product

from the market or for use in a clinical study.

If our product candidates fail to comply with applicable regulatory requirements,

such as good manufacturing practices, a regulatory agency may:

issue warning letters;

require us to enter

into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates

for specific actions, and penalties for noncompliance;

impose other civil

or criminal penalties;

suspend regulatory

suspend any ongoing

clinical trials;

refuse to approve

pending applications or supplements to approved applications filed by us;

impose restrictions

on operations, including costly new manufacturing requirements;

seize or detain

products or require a product recall.

or current or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, we

or they could be subject to enforcement actions and substantial penalties, which could affect our ability to develop, market and

sell our products and may harm our reputation.

we do not currently have any products on the market, once our therapeutic candidates or clinical trials are covered by federal

health care programs, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the

federal, state and foreign governments of the jurisdictions in which we conduct our business.

Healthcare providers, physicians

and third party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain

marketing approval.

Our future arrangements with third party payors and customers may expose us to broadly applicable fraud and

abuse, transparency, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships

through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval.

Restrictions under

applicable federal and state healthcare laws and regulations include, but are not limited to, the following:

Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration,

directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing

or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program

such as Medicare or Medicaid;

federal civil and

criminal false claims laws and civil monetary penalty laws, such as the U.S.

federal FCA, which imposes criminal and civil

penalties, including through civil whistleblower or qui tam actions, against, individuals or entities for knowingly presenting

or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement

to avoid, decrease or conceal an obligation to pay money to the federal government.

In addition, the government may assert

that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false

or fraudulent claim for purposes of the FCA;

HIPAA includes a

fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing

a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material

fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items

Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the

statute or specific intent to violate it in order to have committed a violation;

HIPAA, as amended

by HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health

plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use

or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding,

the privacy, security, and transmission of individually identifiable health information, and require notification to affected

individuals and regulatory authorities of certain breaches of security of individually identifiable health information;

federal and state

consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially

harm consumers;

the federal Physician

Payment Sunshine Act and the implementing regulations, also referred to as “Open Payments,”

issued under the ACA,

which require that manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children’s

Health Insurance Programs report to the Department of Health and Human Services all consulting fees, travel reimbursements,

research grants, and other payments, transfers of value or gifts made to physicians and teaching hospitals with limited exceptions;

analogous state

laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements

and claims involving healthcare items or services reimbursed by nongovernmental third party payors, including private insurers;

and some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance

guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and cell

based therapy manufacturers to report information related to payments to physicians and other healthcare providers or marketing

expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which

differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare

reform, especially in light of the lack of applicable precedent and regulations.

Federal and state enforcement bodies have recently

increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations,

prosecutions, convictions and settlements in the healthcare industry.

Responding to investigations can be time-and resource-consuming

and can divert management’s attention from the business.

Any such investigation or settlement could increase our costs or

otherwise have an adverse effect on our business.

that our business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial

If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil

or criminal penalties, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in

government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could

adversely affect our financial results.

Although effective compliance programs can mitigate the risk of investigation and prosecution

for violations of these laws, these risks cannot be entirely eliminated.

Any action against us for an alleged or suspected violation

could cause us to incur significant legal expenses and could divert our management’s attention from the operation of our

business, even if our defense is successful.

In addition, achieving and sustaining compliance with applicable laws and regulations

may be costly to us in terms of money, time and resources.

based therapies we develop may become subject to unfavorable pricing regulations, third party coverage and reimbursement practices

or healthcare reform initiatives, thereby harming our business.

regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs and cell based therapies vary widely

from country to country.

require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions, and penalties for noncompliance;

impose other civil or criminal penalties;

suspend regulatory approval;

suspend any ongoing clinical trials;

refuse to approve pending applications or supplements to approved applications filed by us;

impose restrictions on operations, including costly new manufacturing requirements;

seize or detain products or require a product recall.

If we or current or future collaborators,

manufacturers, or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement

actions and substantial penalties, which could affect our ability to develop, market and sell our products and may harm our reputation.

Although we do not currently

have any products on the market, once our therapeutic candidates or clinical trials are covered by federal health care programs,

we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign

governments of the jurisdictions in which we conduct our business.

Healthcare providers, physicians and third party payors play

a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval.

future arrangements with third party payors and customers may expose us to broadly applicable fraud and abuse, transparency, and

other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which

we market, sell and distribute our therapeutic candidates for which we obtain marketing approval.

Restrictions under applicable

federal and state healthcare laws and regulations include, but are not limited to, the following:

federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;

federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S.

federal FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against, individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government.

In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;

HIPAA includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.

Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

HIPAA, as amended by HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding, the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;

federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

the federal Physician Payment Sunshine Act and the implementing regulations, also referred to as “Open Payments,”

issued under the ACA, which require that manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children’s Health Insurance Programs report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to physicians and teaching hospitals with limited exceptions;

analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third party payors, including private insurers;

and some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and cell based therapy manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

The scope and enforcement

of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in

light of the lack of applicable precedent and regulations.

Federal and state enforcement bodies have recently increased their

scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions,

convictions and settlements in the healthcare industry.

Responding to investigations can be time-and resource-consuming and can

divert management’s attention from the business.

Any such investigation or settlement could increase our costs or otherwise

have an adverse effect on our business.

Ensuring that our business

arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs.

operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties,

monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting,

healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect our

financial results.

Although effective compliance programs can mitigate the risk of investigation and prosecution for violations

of these laws, these risks cannot be entirely eliminated.

Any action against us for an alleged or suspected violation could cause

us to incur significant legal expenses and could divert our management’s attention from the operation of our business, even

if our defense is successful.

In addition, achieving and sustaining compliance with applicable laws and regulations may be costly

to us in terms of money, time and resources.

Any cell based therapies we develop may

become subject to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives,

thereby harming our business.

The regulations that govern

marketing approvals, pricing, coverage and reimbursement for new drugs and cell based therapies vary widely from country to country.

Some countries require approval of the sale price of a drug before it can be marketed.

In many countries,

the pricing review period begins after marketing or product licensing approval is granted.

In some foreign markets, prescription

pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted.

intend to monitor these regulations, our programs are currently in earlier stages of development and we will not be able to assess

the impact of price regulations for a number of years.

As a result, we might obtain regulatory approval for a product in a particular

country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenues

we are able to generate from the sale of the product in that country.

ability to commercialize any products successfully also will depend in part on the extent to which coverage and reimbursement

for these products and related treatments will be available from government health administration authorities, private health

insurers and other organizations.

However, there may be significant delays in obtaining coverage for newly-approved cell based

Moreover, eligibility for coverage does not necessarily signify that a cell based therapy will be reimbursed in all

cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs.

Also, interim

payments for new cell based therapy if applicable, may be insufficient to cover our costs and may not be made permanent.

even if we succeed in bringing one or more products to the market, these products may not be considered medically necessary or

cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive

Because our programs are in earlier stages of development, we are unable at this time to determine their cost effectiveness,

or the likely level or method of reimbursement.

In addition, obtaining coverage and reimbursement approval of a product from a

government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting

scientific, clinical and cost-effectiveness data for the use of our product on a payor-by-payor basis, with no assurance that

coverage and adequate reimbursement will be obtained.

A payor’s decision to provide coverage for a product does not imply

that an adequate reimbursement rate will be approved.

Further, one payor’s determination to provide coverage for a product

does not assure that other payors will also provide coverage for the product.

Adequate third-party reimbursement may not be available

to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product

candidate that we successfully develop.

Increasingly,

the third party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking

greater upfront discounts, additional rebates and other concessions to reduce the prices for pharmaceutical products.

we are able to charge for any products we develop, or the reimbursement provided for such products, is inadequate in light of

our development and other costs, our return on investment could be adversely affected.

currently expect that certain drugs we develop may need to be administered under the supervision of a physician on an outpatient

Under currently applicable U.S.

law, certain drugs that are not usually self-administered (including injectable cell based

therapies) may be eligible for coverage under Medicare through Medicare Part B.

Specifically, Medicare Part B coverage may be

available for eligible beneficiaries when the following, among other requirements have been satisfied:

the product is reasonable

and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted

standards of medical practice;

the product is typically

furnished incident to a physician’s services;

the indication for

which the product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia

(when used for an off-label use);

the product has

been approved by the FDA.

prices for cell therapies may be reduced by mandatory discounts or rebates required by government healthcare programs or private

payors and by any future relaxation of laws that presently restrict imports of drugs and cell based therapy from countries where

they may be sold at lower prices than in the U.S.

Reimbursement rates under Medicare Part B would depend in part on whether the

newly approved product would be eligible for a unique billing code.

Self-administered, outpatient drugs and cell based therapies

are typically reimbursed under Medicare Part D, and cell based therapies that are administered in an inpatient hospital setting

are typically reimbursed under Medicare Part A under a bundled payment.

It is difficult for us to predict how Medicare coverage

and reimbursement policies will be applied to our products in the future and coverage and reimbursement under different federal

healthcare programs are not always consistent.

Medicare reimbursement rates may also reflect budgetary constraints placed on the

Medicare program.

party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates.

coverage policies and limitations may rely, in part, on compendia listings for approved therapeutics.

Our inability to promptly

obtain relevant compendia listings, coverage, and adequate reimbursement from both government-funded and private payors for new

cell based therapies that we develop and for which we obtain regulatory approval could have a material adverse effect on our operating

results, our ability to raise capital needed to commercialize products and our financial condition.

expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage

criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product.

reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from

private payors.

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to

generate revenue, attain profitability or commercialize our cell based therapies, once marketing approval is obtained.

believe that the efforts of governments and third party payors to contain or reduce the cost of healthcare and legislative and

regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of

pharmaceutical and biopharmaceutical companies.

A number of legislative and regulatory changes in the healthcare system in the

and other major healthcare markets have been proposed, and such efforts have expanded substantially in recent years.

developments could, directly or indirectly, affect our ability to sell our products, if approved, at a favorable price.

in the United States, in 2010, the U.S.

Congress passed the ACA, a sweeping law intended to broaden access to health insurance,

reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements

for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional policy

Among the provisions of the ACA addressing coverage and reimbursement of pharmaceutical products, of importance to our

potential therapeutic candidates are the following:

increases to pharmaceutical

manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate

on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed

the expansion of

the 340B Drug Pricing Program to require discounts for “covered outpatient drugs”

sold to certain children’s

hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals;

requirements imposed

on pharmaceutical companies are required to offer discounts on brand-name cell based therapy to patients who fall within the

Medicare Part D coverage gap, commonly referred to as the “Donut Hole”;

requirements imposed

on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company’s

market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid,

Department of Veterans Affairs and Department of Defense;

for products classified

as biologics, marketing approval for a follow-on biologic product may not become effective until 12 years after the date on

which the reference innovator biologic product was first licensed by the FDA, with a possible six-month extension for pediatric

After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely

to reduce the pricing for the innovator product and could affect our profitability if our products are classified as biologics.

pursuant to the health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, is

working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other

innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative,

the Comprehensive Primary Care Initiative, the Duals Demonstration, and other models.

The continued development and expansion

of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved

therapeutics administered by these organizations.

The healthcare

industry is heavily regulated in the U.S.

at the federal, state, and local levels, and our failure to comply with applicable requirements

may subject us to penalties and negatively affect our financial condition.

a healthcare company, our operations, clinical trial activities and interactions with healthcare providers may be subject to extensive

regulation in the U.S., particularly if we receive FDA approval for any of its products in the future.

For example, if we receive

FDA approval for a product for which reimbursement is available under a federal healthcare program (e.g., Medicare, Medicaid),

it would be subject to a variety of federal laws and regulations, including those that prohibit the filing of false or improper

claims for payment by federal healthcare programs (e.g.

the federal False Claims Act), prohibit unlawful inducements for the referral

of business reimbursable by federal healthcare programs (e.g.

the federal Anti-Kickback Statute), and require disclosure of certain

payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals or Open Payments.

We are not able

to predict how third parties will interpret these laws and apply applicable governmental guidance and may challenge our practices

and activities under one or more of these laws.

If our past or present operations are found to be in violation of any of these

laws, we could be subject to civil and criminal penalties, which could hurt our business, our operations and financial condition.

federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,

soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return

for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare,

Medicaid or other federal healthcare programs.

In many countries, the pricing review period

begins after marketing or product licensing approval is granted.

In some foreign markets, prescription pharmaceutical pricing remains

subject to continuing governmental control even after initial approval is granted.

Although we intend to monitor these regulations,

our programs are currently in earlier stages of development and we will not be able to assess the impact of price regulations for

a number of years.

As a result, we might obtain regulatory approval for a product in a particular country, but then be subject

to price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate

from the sale of the product in that country.

Our ability to commercialize

any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related

treatments will be available from government health administration authorities, private health insurers and other organizations.

However, there may be significant delays in obtaining coverage for newly-approved cell based therapies.

Moreover, eligibility for

coverage does not necessarily signify that a cell based therapy will be reimbursed in all cases or at a rate that covers our costs,

including research, development, manufacture, sale and distribution costs.

Also, interim payments for new cell based therapy if

applicable, may be insufficient to cover our costs and may not be made permanent.

Thus, even if we succeed in bringing one or more

products to the market, these products may not be considered medically necessary or cost-effective, and the amount reimbursed for

any products may be insufficient to allow us to sell our products on a competitive basis.

Because our programs are in earlier stages

of development, we are unable at this time to determine their cost effectiveness, or the likely level or method of reimbursement.

In addition, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming

and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for

the use of our product on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained.

A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.

Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide

coverage for the product.

Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient

to realize an appropriate return on our investment in product development.

If reimbursement is not available or is available only

at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.

Increasingly, the third

party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater

upfront discounts, additional rebates and other concessions to reduce the prices for pharmaceutical products.

If the price we are

able to charge for any products we develop, or the reimbursement provided for such products, is inadequate in light of our development

and other costs, our return on investment could be adversely affected.

We currently expect that

certain drugs we develop may need to be administered under the supervision of a physician on an outpatient basis.

Under currently

applicable U.S.

law, certain drugs that are not usually self-administered (including injectable cell based therapies) may be eligible

for coverage under Medicare through Medicare Part B.

Specifically, Medicare Part B coverage may be available for eligible beneficiaries

when the following, among other requirements have been satisfied:

the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice;

the product is typically furnished incident to a physician’s services;

the indication for which the product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia (when used for an off-label use);

the product has been approved by the FDA.

Average prices for cell

therapies may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by

any future relaxation of laws that presently restrict imports of drugs and cell based therapy from countries where they may be

sold at lower prices than in the U.S.

Reimbursement rates under Medicare Part B would depend in part on whether the newly approved

product would be eligible for a unique billing code.

Self-administered, outpatient drugs and cell based therapies are typically

reimbursed under Medicare Part D, and cell based therapies that are administered in an inpatient hospital setting are typically

reimbursed under Medicare Part A under a bundled payment.

It is difficult for us to predict how Medicare coverage and reimbursement

policies will be applied to our products in the future and coverage and reimbursement under different federal healthcare programs

are not always consistent.

Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.

Third party payors often

rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates.

These coverage policies

and limitations may rely, in part, on compendia listings for approved therapeutics.

Our inability to promptly obtain relevant compendia

listings, coverage, and adequate reimbursement from both government-funded and private payors for new cell based therapies that

we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability

to raise capital needed to commercialize products and our financial condition.

We expect that these and

other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement,

and in additional downward pressure on the price that we receive for any approved product.

Any reduction in reimbursement from

Medicare or other government-funded programs may result in a similar reduction in payments from private payors.

The implementation

of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability

or commercialize our cell based therapies, once marketing approval is obtained.

We believe that the efforts

of governments and third party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden

the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical

A number of legislative and regulatory changes in the healthcare system in the U.S.

and other major healthcare markets

have been proposed, and such efforts have expanded substantially in recent years.

These developments could, directly or indirectly,

affect our ability to sell our products, if approved, at a favorable price.

For example, in the United States, in 2010, the U.S.

Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health

spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries,

impose new taxes and fees on the health industry and impose additional policy reforms.

Among the provisions of the ACA addressing

coverage and reimbursement of pharmaceutical products, of importance to our potential therapeutic candidates are the following:

increases to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans;

the expansion of the 340B Drug Pricing Program to require discounts for “covered outpatient drugs”

sold to certain children’s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals;

requirements imposed on pharmaceutical companies are required to offer discounts on brand-name cell based therapy to patients who fall within the Medicare Part D coverage gap, commonly referred to as the “Donut Hole”;

requirements imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company’s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department of Defense;

for products classified as biologics, marketing approval for a follow-on biologic product may not become effective until 12 years after the date on which the reference innovator biologic product was first licensed by the FDA, with a possible six-month extension for pediatric products.

After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for the innovator product and could affect our profitability if our products are classified as biologics.

Separately, pursuant to

the health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, is working with

various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models

of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Comprehensive

Primary Care Initiative, the Duals Demonstration, and other models.

The continued development and expansion of ACOs and other innovative

models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered

by these organizations.

The healthcare industry is heavily regulated

at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties

and negatively affect our financial condition.

As a healthcare company,

our operations, clinical trial activities and interactions with healthcare providers may be subject to extensive regulation in

the U.S., particularly if we receive FDA approval for any of its products in the future.

For example, if we receive FDA approval

for a product for which reimbursement is available under a federal healthcare program (e.g., Medicare, Medicaid), it would be subject

to a variety of federal laws and regulations, including those that prohibit the filing of false or improper claims for payment

by federal healthcare programs (e.g.

the federal False Claims Act), prohibit unlawful inducements for the referral of business

reimbursable by federal healthcare programs (e.g.

the federal Anti-Kickback Statute), and require disclosure of certain payments

or other transfers of value made to U.S.-licensed physicians and teaching hospitals or Open Payments.

We are not able to predict

how third parties will interpret these laws and apply applicable governmental guidance and may challenge our practices and activities

under one or more of these laws.

If our past or present operations are found to be in violation of any of these laws, we could

be subject to civil and criminal penalties, which could hurt our business, our operations and financial condition.

The federal Anti-Kickback

Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving

any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing,

ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal

healthcare programs.

The term remuneration has been interpreted broadly to include anything of value.

The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers,

purchasers, and formulary managers on the other.

There are a number of statutory exceptions and regulatory safe harbors protecting

some common activities from prosecution.

The exceptions and safe harbors are drawn narrowly and practices that involve remuneration

that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not

qualify for an exception or safe harbor.

Failure to meet all of the requirements of a particular applicable statutory exception

or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute.

Instead, the legality of the

arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.

practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.

Additionally,

the intent standard under the Anti-Kickback Statute was amended by the ACA, to a stricter standard such that a person or entity

no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-

Kickback Statute constitutes a false or fraudulent claim for purposes of the federal FCA.

civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have

presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item

or service that was not provided as claimed or is false or fraudulent.

false claims and false statement laws, including the federal FCA, prohibit, among other things, any person or entity from knowingly

presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal healthcare programs,

including Medicare and Medicaid, or knowingly making, using, or causing to be made or used a false record or statement material

to a false or fraudulent claim to the federal government.

The Anti-Kickback Statute

has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and

formulary managers on the other.

There are a number of statutory exceptions and regulatory safe harbors protecting some common

activities from prosecution.

The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may

be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for

an exception or safe harbor.

Failure to meet all of the requirements of a particular applicable statutory exception or regulatory

safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute.

Instead, the legality of the arrangement

will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances.

Our practices may

not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.

Additionally, the intent

standard under the Anti-Kickback Statute was amended by the ACA, to a stricter standard such that a person or entity no longer

needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti- Kickback Statute

constitutes a false or fraudulent claim for purposes of the federal FCA.

The civil monetary penalties

statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be

presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided

as claimed or is false or fraudulent.

Federal false claims and

false statement laws, including the federal FCA, prohibit, among other things, any person or entity from knowingly presenting,

or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal healthcare programs, including

Medicare and Medicaid, or knowingly making, using, or causing to be made or used a false record or statement material to a false

or fraudulent claim to the federal government.

A claim includes “any request or demand”

for money or property

presented to the U.S.

For instance, historically, pharmaceutical and other healthcare companies have been prosecuted

under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal

programs for the product.

for money or property presented

For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these

laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for

Other companies have been prosecuted for causing false claims to be submitted because of the companies’

marketing of the product for unapproved, off-label, and thus generally non-reimbursable, uses.

prohibits, among other offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including

private payors, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent

statement in connection with the delivery of or payment for items or services under a health care benefit program.

To the extent

that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the

privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable

health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information,

and requires the reporting of certain security breaches to healthcare provider customers with respect to such information.

Additionally,

many states have enacted similar laws that may impose more stringent requirements on entities like ours.

Failure to comply with

applicable laws and regulations could result in substantial penalties and adversely affect our financial condition and results

of operations.

states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and

other state programs, or, in several states, apply regardless of the payor.

Additionally, to the extent that our product is sold

in a foreign country, we may be subject to similar foreign laws.

products, once approved, may be eligible for coverage under Medicare and Medicaid, among other government healthcare programs.

Accordingly, we may be subject to a number of obligations based on their participation in these programs, such as a requirement

to calculate and report certain price reporting metrics to the government, such as average sales price (ASP) and best price.

may apply in some cases when such metrics are not submitted accurately and timely.

Further, these prices for drugs may be reduced

by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of

laws that presently restrict imports of drugs and biological products from countries where they may be sold at lower prices than

in the United States.

It is difficult to predict how Medicare coverage and reimbursement policies will be applied to our products

in the future and coverage and reimbursement under different federal healthcare programs are not always consistent.

Medicare reimbursement

rates may also reflect budgetary constraints placed on the Medicare program.

order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale

distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship

products into the state even if such manufacturers or distributors have no place of business within the state.

Some states also

impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including

some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves

through the distribution chain.

Several states have enacted legislation requiring pharmaceutical and biotechnology companies to

establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,

pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies

and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies

for use in sales and marketing, and to prohibit certain other sales and marketing practices.

All of our activities are potentially

subject to federal and state consumer protection and unfair competition laws.

our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental

regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative

penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions,

private “qui tam”

actions brought by individual whistleblowers in the name of the government, or refusal to allow

us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and

future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate

our business and our results of operations.

to obtain reimbursement or funding from the federal government may be impacted by possible reductions in federal spending.

federal government agencies currently face potentially significant spending reductions.

The Budget Control Act of 2011, or the

BCA, established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt

level of at least $1.2 trillion.

of the product for unapproved, off-label, and thus generally non-reimbursable, uses.

HIPAA prohibits, among

other offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors,

or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in

connection with the delivery of or payment for items or services under a health care benefit program.

To the extent that we act

as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and

security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information,

mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires

the reporting of certain security breaches to healthcare provider customers with respect to such information.

Additionally, many

states have enacted similar laws that may impose more stringent requirements on entities like ours.

Failure to comply with applicable

laws and regulations could result in substantial penalties and adversely affect our financial condition and results of operations.

Many states also have similar

fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or,

in several states, apply regardless of the payor.

Additionally, to the extent that our product is sold in a foreign country, we

may be subject to similar foreign laws.

Our products, once approved,

may be eligible for coverage under Medicare and Medicaid, among other government healthcare programs.

Accordingly, we may be subject

to a number of obligations based on their participation in these programs, such as a requirement to calculate and report certain

price reporting metrics to the government, such as average sales price (ASP) and best price.

Penalties may apply in some cases

when such metrics are not submitted accurately and timely.

Further, these prices for drugs may be reduced by mandatory discounts

or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict

imports of drugs and biological products from countries where they may be sold at lower prices than in the United States.

difficult to predict how Medicare coverage and reimbursement policies will be applied to our products in the future and coverage

and reimbursement under different federal healthcare programs are not always consistent.

Medicare reimbursement rates may also

reflect budgetary constraints placed on the Medicare program.

In order to distribute

products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors

of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into

the state even if such manufacturers or distributors have no place of business within the state.

Some states also impose requirements

on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that

require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution

Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance

programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials

and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities

from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing,

and to prohibit certain other sales and marketing practices.

All of our activities are potentially subject to federal and state

consumer protection and unfair competition laws.

If our operations are found

to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply

to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages,

fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private “qui

actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government

contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment

or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of

Our ability to obtain reimbursement or funding

from the federal government may be impacted by possible reductions in federal spending.

federal government

agencies currently face potentially significant spending reductions.

The Budget Control Act of 2011, or the BCA, established a

Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least

$1.2 trillion.

That committee did not draft a proposal by the BCA’s deadline.

As a result, automatic cuts,

referred to as sequestration, in various federal programs were scheduled to take place, beginning in January 2013, although the

American Taxpayer Relief Act of 2012 delayed the BCA’s automatic cuts until March 1, 2013.

While the Medicare program’s

eligibility and scope of benefits are generally exempt from these cuts, Medicare payments to providers and Part D health plans

are not exempt.

The BCA did, however, provide that the Medicare cuts to providers and Part D health plans would not exceed two

President Obama issued the sequestration order on March 1, 2013, and cuts went into effect on April 1, 2013.

Additionally,

the Bipartisan Budget Act of 2015 extended sequestration for Medicare through fiscal year 2027.

federal budget remains in flux, which could, among other things, cut Medicare payments to providers.

The Medicare program

is frequently mentioned as a target for spending cuts.

The full impact on our business of any future cuts in Medicare or other

programs is uncertain.

In addition, we cannot predict any impact President Trump’s administration and the U.S.

may have on the federal budget.

If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of

relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current levels.

Amounts allocated

to federal grants and contracts may be reduced or eliminated.

These reductions may also impact the ability of relevant agencies

to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability

to develop, market and sell any products we may develop.

Related to Doing Business in China

become directly subject to the recent scrutiny, criticism and negative publicity involving certain U.S.-listed Chinese companies,

we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock

price and reputation and could result in a loss of your investment in our stock, especially if such matter cannot be addressed

and resolved quickly.

public companies that have substantially all of their operations in China, particularly companies like us which have completed

so-called reverse merger transactions, have been the subject of intense scrutiny, criticism and negative publicity by investors,

short sellers, financial commentators and regulatory agencies, such as the United States Securities and Exchange Commission.

of the scrutiny, criticism and negative publicity has centered around financial and accounting irregularities and mistakes, inadequate

corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud.

As a result of the scrutiny,

criticism and negative publicity, the publicly traded stock of many U.S.

listed Chinese companies has sharply decreased in value

and, in some cases, has become virtually worthless.

Many of these companies are now subject to shareholder lawsuits, SEC enforcement

actions and are conducting internal and external investigations into the allegations.

It is not clear what affect this sector-wide

scrutiny, criticism and negative publicity will have on our company, our business and our stock price.

If we become the subject

of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend significant resources

to investigate such allegations and/or defend our company.

This situation could be costly and time consuming and distract our

management from growing our company.

If such allegations are not proven to be groundless, our company and business operations

will be severely impacted and your investment in our stock could be rendered worthless.

Adverse changes in political

and economic policies of the PRC government could impede the overall economic growth of China, which could reduce the demand for

our products and damage our business.

we generate our revenue in China although we intend to pursue various opportunities in the United States and our headquarters

is based in the United States.

Accordingly, our business, financial condition, results of operations and prospects are affected

significantly by economic, political and legal developments in China.

The PRC economy differs from the economies of most developed

countries in many respects, including:

the higher level

of government involvement;

the early stage

of development of the market-oriented sector of the economy;

the rapid growth

the higher level

of control over foreign exchange;

the allocation of

the PRC economy has been transitioning from a planned economy to a more market-oriented economy, the PRC government has implemented

various measures to encourage economic growth and guide the allocation of resources.

While these measures may benefit the overall

PRC economy, they may also have a negative effect on us or the healthcare industry in general.

the PRC government has in recent years implemented measures emphasizing the utilization of market forces for economic reform,

the PRC government continues to exercise significant control over economic growth in China through the allocation of resources,

controlling payment of foreign currency-denominated obligations, setting monetary policy and imposing policies that impact particular

industries or companies in different ways.

adverse change in the economic conditions or government policies in China could have a material adverse effect on the overall

economic growth and the level of new healthcare investments and expenditures in China, which in turn could lead to a reduction

in demand for our services and consequently have a material adverse effect on our business and prospects.

Uncertainties

with respect to the PRC legal system could limit the legal protections available to you and us.

conduct substantially all of our business through our operating subsidiaries in the PRC.

Our operating subsidiaries are generally

subject to laws and regulations applicable to foreign investments in China and, in particular, laws applicable to foreign-invested

The PRC legal system is based on written statutes, and prior court decisions may be cited for reference but have

limited precedential value.

Since 1979, a series of new PRC laws and regulations have significantly enhanced the protections afforded

to various forms of foreign investments in China.

However, since the PRC legal system continues to rapidly evolve, the interpretations

of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties,

which may limit legal protections available to you and us.

In addition, any litigation in China may be protracted and result in

substantial costs and diversion of resources and management attention.

In addition, all of our executive officers and almost all

of our directors are residents of China and not of the United States, and substantially all the assets of these persons are located

outside the United States.

As a result, it could be difficult for investors to affect service of process in the United States

or to enforce a judgment obtained in the United States against our Chinese operations and subsidiaries.

government exerts substantial influence over the manner in which we must conduct our business activities.

PRC government has exercised and continues to exercise substantial control over virtually every sector of the Chinese economy

through regulation and state ownership.

As a result, automatic cuts, referred to as

sequestration, in various federal programs were scheduled to take place, beginning in January 2013, although the American Taxpayer

Relief Act of 2012 delayed the BCA’s automatic cuts until March 1, 2013.

While the Medicare program’s eligibility and

scope of benefits are generally exempt from these cuts, Medicare payments to providers and Part D health plans are not exempt.

The BCA did, however, provide that the Medicare cuts to providers and Part D health plans would not exceed two percent.

Obama issued the sequestration order on March 1, 2013, and cuts went into effect on April 1, 2013.

Additionally, the Bipartisan

Budget Act of 2015 extended sequestration for Medicare through fiscal year 2027.

federal budget

remains in flux, which could, among other things, cut Medicare payments to providers.

The Medicare program is frequently mentioned

as a target for spending cuts.

The full impact on our business of any future cuts in Medicare or other programs is uncertain.

addition, we cannot predict any impact President Trump’s administration and the U.S.

Congress may have on the federal budget.

If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the

FDA or the National Institutes of Health, to continue to function at current levels.

Amounts allocated to federal grants and contracts

may be reduced or eliminated.

These reductions may also impact the ability of relevant agencies to timely review and approve drug

research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any

products we may develop.

Risks Related to Doing Business in China

If we become directly subject to the recent

scrutiny, criticism and negative publicity involving certain U.S.-listed Chinese companies, we may have to expend significant resources

to investigate and resolve the matter which could harm our business operations, stock price and reputation and could result in

a loss of your investment in our stock, especially if such matter cannot be addressed and resolved quickly.

Recently, U.S.

public companies

that have substantially all of their operations in China, particularly companies like us which have completed so-called reverse

merger transactions, have been the subject of intense scrutiny, criticism and negative publicity by investors, short sellers, financial

commentators and regulatory agencies, such as the United States Securities and Exchange Commission.

Much of the scrutiny, criticism

and negative publicity has centered around financial and accounting irregularities and mistakes, inadequate corporate governance

policies or a lack of adherence thereto and, in many cases, allegations of fraud.

As a result of the scrutiny, criticism and negative

publicity, the publicly traded stock of many U.S.

listed Chinese companies has sharply decreased in value and, in some cases, has

become virtually worthless.

Many of these companies are now subject to shareholder lawsuits, SEC enforcement actions and are conducting

internal and external investigations into the allegations.

It is not clear what affect this sector-wide scrutiny, criticism and

negative publicity will have on our company, our business and our stock price.

If we become the subject of any unfavorable allegations,

whether such allegations are proven to be true or untrue, we will have to expend significant resources to investigate such allegations

and/or defend our company.

This situation could be costly and time consuming and distract our management from growing our company.

If such allegations are not proven to be groundless, our company and business operations will be severely impacted and your investment

in our stock could be rendered worthless.

Adverse changes in political and economic policies of the PRC

government could impede the overall economic growth of China, which could reduce the demand for our products and damage our business.

Presently, we generate

our revenue in China although we intend to pursue various opportunities in the United States and our headquarters is based in the

United States.

Accordingly, our business, financial condition, results of operations and prospects are affected significantly by

economic, political and legal developments in China.

The PRC economy differs from the economies of most developed countries in

many respects, including:

the higher level of government involvement;

the early stage of development of the market-oriented sector of the economy;

the rapid growth rate;

the higher level of control over foreign exchange;

the allocation of resources.

As the PRC economy has

been transitioning from a planned economy to a more market-oriented economy, the PRC government has implemented various measures

to encourage economic growth and guide the allocation of resources.

While these measures may benefit the overall PRC economy, they

may also have a negative effect on us or the healthcare industry in general.

Although the PRC government

has in recent years implemented measures emphasizing the utilization of market forces for economic reform, the PRC government continues

to exercise significant control over economic growth in China through the allocation of resources, controlling payment of foreign

currency-denominated obligations, setting monetary policy and imposing policies that impact particular industries or companies

in different ways.

Any adverse change in the

economic conditions or government policies in China could have a material adverse effect on the overall economic growth and the

level of new healthcare investments and expenditures in China, which in turn could lead to a reduction in demand for our services

and consequently have a material adverse effect on our business and prospects.

Uncertainties with respect to the PRC legal

system could limit the legal protections available to you and us.

We conduct substantially

all of our business through our operating subsidiaries in the PRC.

Our operating subsidiaries are generally subject to laws and

regulations applicable to foreign investments in China and, in particular, laws applicable to foreign-invested enterprises.

PRC legal system is based on written statutes, and prior court decisions may be cited for reference but have limited precedential

Since 1979, a series of new PRC laws and regulations have significantly enhanced the protections afforded to various forms

of foreign investments in China.

However, since the PRC legal system continues to rapidly evolve, the interpretations of many laws,

regulations and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties, which

may limit legal protections available to you and us.

In addition, any litigation in China may be protracted and result in substantial

costs and diversion of resources and management attention.

In addition, all of our executive officers and almost all of our directors

are residents of China and not of the United States, and substantially all the assets of these persons are located outside the

United States.

As a result, it could be difficult for investors to affect service of process in the United States or to enforce

a judgment obtained in the United States against our Chinese operations and subsidiaries.

The PRC government exerts substantial influence

over the manner in which we must conduct our business activities.

The PRC government has

exercised and continues to exercise substantial control over virtually every sector of the Chinese economy through regulation and

state ownership.

Our ability to operate in China may be harmed by changes in its laws and regulations.

We believe that our operations in China are in material compliance with all applicable legal and regulatory requirements.

the central or local governments of the jurisdictions in which we operate may impose new, stricter regulations or interpretations

of existing regulations that would require additional expenditures and efforts on our part to ensure our compliance with such

regulations or interpretations.

government actions in the future, including any decision not to continue to support recent economic reforms and to return to a

more centrally planned economy or regional or local variations in the implementation of economic policies, could have a significant

effect on economic conditions in China or particular regions thereof.

be unable to complete a business combination transaction efficiently or on favorable terms due to complicated merger and acquisition

regulations implemented on September 8, 2006.

recent PRC Regulation on Mergers and Acquisitions of Domestic Companies by Foreign Investors also governs the approval process

by which a PRC company may participate in an acquisition of its assets or its equity interests.

Depending on the structure of

the transaction, the new regulation will require the Chinese parties to make a series of applications and supplemental applications

to the government agencies.

In some instances, the application process may require the presentation of economic data concerning

a transaction, including appraisals of the target business and evaluations of the acquirer, which are designed to allow the government

to assess the transaction.

Government approvals will have expiration dates by which a transaction must be completed and reported

to the government agencies.

Compliance with the new regulations is likely to be more time consuming and expensive than in the

past and the government can now exert more control over the combination of two businesses.

Accordingly, due to the new regulation,

our ability to engage in business combination transactions is extremely complicated, time consuming and expensive, and we may

not be able to negotiate a transaction that is acceptable to our stockholders or sufficiently protect their interests in a transaction.

new regulation allows PRC government agencies to assess the economic terms of a business combination transaction.

business combination transaction may have to submit to the Ministry of Commerce, or MOFCOM, and the other government agencies

an appraisal report, an evaluation report and the acquisition agreement, all of which form part of the application for approval,

depending on the structure of the transaction.

The regulations also prohibit a transaction at an acquisition price obviously lower

than the appraised value of the Chinese business or assets and in certain transaction structures, require that consideration must

be paid within defined periods, generally not in excess of a year.

The regulation also limits our ability to negotiate various

terms of the acquisition, including aspects of the initial consideration, contingent consideration, holdback provisions, indemnification

provisions and provisions relating to the assumption and allocation of assets and liabilities.

Transaction structures involving

trusts, nominees and similar entities are prohibited.

Therefore, such regulation may impede our ability to negotiate and complete

a business combination transaction on financial terms that satisfy our investors and protect our stockholders’

the current Enterprise Income Tax, or EIT, law, we may be classified as a “resident enterprise”

Such classification

will likely result in unfavorable tax consequences to us and our non- PRC stockholders.

are a holding company incorporated under the laws of Delaware.

We conduct substantially all of our business through our wholly-owned

and majority-owned subsidiaries, and we derive all of our income from these entities.

Prior to January 1, 2008, dividends derived

by foreign enterprises from business operations in China were not subject to the Chinese enterprise income tax.

However, such

tax exemption ceased as of January 1, 2008 and thereafter with the effectiveness of the new EIT law.

the EIT law, if we are not deemed to be a “resident enterprise”

for Chinese tax purposes, a withholding tax at the

rate of 10% would be applicable to any dividends paid by our Chinese subsidiaries to us.

However, if we are deemed to be a “resident

enterprise”

We believe that our operations

in China are in material compliance with all applicable legal and regulatory requirements.

However, the central or local governments

of the jurisdictions in which we operate may impose new, stricter regulations or interpretations of existing regulations that would

require additional expenditures and efforts on our part to ensure our compliance with such regulations or interpretations.

Accordingly, government

actions in the future, including any decision not to continue to support recent economic reforms and to return to a more centrally

planned economy or regional or local variations in the implementation of economic policies, could have a significant effect on

economic conditions in China or particular regions thereof.

We may be unable to complete a business

combination transaction efficiently or on favorable terms due to complicated merger and acquisition regulations implemented on

September 8, 2006.

The recent PRC Regulation

on Mergers and Acquisitions of Domestic Companies by Foreign Investors also governs the approval process by which a PRC company

may participate in an acquisition of its assets or its equity interests.

Depending on the structure of the transaction, the new

regulation will require the Chinese parties to make a series of applications and supplemental applications to the government agencies.

In some instances, the application process may require the presentation of economic data concerning a transaction, including appraisals

of the target business and evaluations of the acquirer, which are designed to allow the government to assess the transaction.

approvals will have expiration dates by which a transaction must be completed and reported to the government agencies.

with the new regulations is likely to be more time consuming and expensive than in the past and the government can now exert more

control over the combination of two businesses.

Accordingly, due to the new regulation, our ability to engage in business combination

transactions is extremely complicated, time consuming and expensive, and we may not be able to negotiate a transaction that is

acceptable to our stockholders or sufficiently protect their interests in a transaction.

The new regulation allows

PRC government agencies to assess the economic terms of a business combination transaction.

Parties to a business combination transaction

may have to submit to the Ministry of Commerce, or MOFCOM, and the other government agencies an appraisal report, an evaluation

report and the acquisition agreement, all of which form part of the application for approval, depending on the structure of the

The regulations also prohibit a transaction at an acquisition price obviously lower than the appraised value of the

Chinese business or assets and in certain transaction structures, require that consideration must be paid within defined periods,

generally not in excess of a year.

The regulation also limits our ability to negotiate various terms of the acquisition, including

aspects of the initial consideration, contingent consideration, holdback provisions, indemnification provisions and provisions

relating to the assumption and allocation of assets and liabilities.

Transaction structures involving trusts, nominees and similar

entities are prohibited.

Therefore, such regulation may impede our ability to negotiate and complete a business combination transaction

on financial terms that satisfy our investors and protect our stockholders’

economic interests.

Under the current Enterprise Income Tax,

or EIT, law, we may be classified as a “resident enterprise”

Such classification will likely result in unfavorable

tax consequences to us and our non- PRC stockholders.

We are a holding company

incorporated under the laws of Delaware.

We conduct substantially all of our business through our wholly-owned and majority-owned

subsidiaries, and we derive all of our income from these entities.

Prior to January 1, 2008, dividends derived by foreign enterprises

from business operations in China were not subject to the Chinese enterprise income tax.

However, such tax exemption ceased as

of January 1, 2008 and thereafter with the effectiveness of the new EIT law.

Under the EIT law, if we

are not deemed to be a “resident enterprise”

for Chinese tax purposes, a withholding tax at the rate of 10% would be

applicable to any dividends paid by our Chinese subsidiaries to us.

However, if we are deemed to be a “resident enterprise”

established outside of China whose “place of effective management”

is located in China, we would

be classified as a resident enterprise for Chinese tax purposes and thus would be subject to an enterprise income tax rate of

25% on all of our income on a worldwide basis.

regulations promulgated pursuant to the EIT law define the term “place of effective management”

as “establishments

that carry out substantial and overall management and control over the manufacturing and business operations, personnel, accounting,

properties, etc.

of an enterprise.”

The State Administration of Taxation issued a SAT Circular 82 on April 22, 2009, which

provides that the “place of effective management”

of a Chinese-controlled overseas-incorporated enterprise is located

in China if the following requirements are satisfied:

(i) the senior management and core management departments in charge of its

daily operations function are mainly located in the PRC;

(ii) its financial and human resources decisions are subject to determination

or approval by persons or bodies located in the PRC;

(iii) its major assets, accounting books, company seals, and minutes and

files of its board and shareholders’

is located in China, we would be classified as a

resident enterprise for Chinese tax purposes and thus would be subject to an enterprise income tax rate of 25% on all of our income

on a worldwide basis.

The regulations promulgated

pursuant to the EIT law define the term “place of effective management”

as “establishments that carry out substantial

and overall management and control over the manufacturing and business operations, personnel, accounting, properties, etc.

enterprise.”

The State Administration of Taxation issued a SAT Circular 82 on April 22, 2009, which provides that the “place

of effective management”

of a Chinese-controlled overseas-incorporated enterprise is located in China if the following requirements

are satisfied:

(i) the senior management and core management departments in charge of its daily operations function are mainly

located in the PRC;

(ii) its financial and human resources decisions are subject to determination or approval by persons or bodies

located in the PRC;

(iii) its major assets, accounting books, company seals, and minutes and files of its board and shareholders’

meetings are located or kept in the PRC;

and (iv) no less than half of the enterprise’s

directors or senior management with voting rights reside in the PRC.

SAT Circular 82 applies only to overseas registered enterprises

controlled by PRC enterprises, not to those controlled by PRC individuals.

If our non-PRC incorporated entities are deemed PRC

tax residents, such entities would be subject to PRC tax under the EIT law.

have analyzed the applicability of the EIT law and related regulations, and for each of the applicable periods presented, we have

not accrued for PRC tax on such basis.

In addition, although under the EIT law and the related regulations dividends paid to us

by our PRC subsidiaries would qualify as “tax-exempted income,”

we cannot assure you that such dividends will not

be subject to a 10% withholding tax, as the PRC foreign exchange control authorities, which enforce the withholding tax, have

not yet issued guidance with respect to the processing of outbound remittances to entities that are treated as resident enterprises

for PRC enterprise income tax purposes.

As a result of such changes, our historical operating results will not be indicative of

our operating results for future periods and the value of our shares of common stock may be adversely affected.

We are actively

monitoring the possibility of “resident enterprise”

treatment and are evaluating appropriate organizational changes

to avoid this treatment, to the extent possible.

be subject to fines and legal sanctions if we or our Chinese employees fail to comply with PRC regulations relating to employee

stock options granted by overseas listed companies to PRC citizens.

December 25, 2006, the People’s Bank of China issued the Administration Measures on Individual Foreign Exchange Control,

and its Implementation Rules were issued by the State Administration of Foreign Exchange, or SAFE, on January 5, 2007.

effect on February 1, 2007.

Under these regulations, all foreign exchange matters involved in an employee stock holding plan,

stock option plan or similar plan in which PRC citizens’

participation requires approval from the SAFE or its authorized

On March 28, 2007, the SAFE issued the Application Procedure for Foreign Exchange Administration for Domestic Individuals

Participating in Employee Stock Holding Plans or Stock Option Plans of Overseas Listed Companies, or Notice 78.

Under Notice 78,

PRC individuals who participate in an employee stock option holding plan or a stock option plan of an overseas listed company

are required, through a PRC domestic agent or PRC subsidiary of the overseas listed company, to register with the SAFE and complete

certain other procedures.

If we and our Chinese employees are granted shares or stock options pursuant to our share incentive

plan they would be subject to Notice 78.

However, in practice, there are significant uncertainties with regard to the interpretation

and implementation of Notice 78.

and (iv) no less than half of the enterprise’s directors or senior management with

voting rights reside in the PRC.

SAT Circular 82 applies only to overseas registered enterprises controlled by PRC enterprises,

not to those controlled by PRC individuals.

If our non-PRC incorporated entities are deemed PRC tax residents, such entities would

be subject to PRC tax under the EIT law.

We have analyzed the applicability

of the EIT law and related regulations, and for each of the applicable periods presented, we have not accrued for PRC tax on such

In addition, although under the EIT law and the related regulations dividends paid to us by our PRC subsidiaries would qualify

as “tax-exempted income,”

we cannot assure you that such dividends will not be subject to a 10% withholding tax, as

the PRC foreign exchange control authorities, which enforce the withholding tax, have not yet issued guidance with respect to the

processing of outbound remittances to entities that are treated as resident enterprises for PRC enterprise income tax purposes.

As a result of such changes, our historical operating results will not be indicative of our operating results for future periods

and the value of our shares of common stock may be adversely affected.

We are actively monitoring the possibility of “resident

enterprise”

treatment and are evaluating appropriate organizational changes to avoid this treatment, to the extent possible.

We may be subject to fines and legal sanctions

if we or our Chinese employees fail to comply with PRC regulations relating to employee stock options granted by overseas listed

companies to PRC citizens.

On December 25, 2006, the

People’s Bank of China issued the Administration Measures on Individual Foreign Exchange Control, and its Implementation

Rules were issued by the State Administration of Foreign Exchange, or SAFE, on January 5, 2007.

Both took effect on February 1,

Under these regulations, all foreign exchange matters involved in an employee stock holding plan, stock option plan or similar

plan in which PRC citizens’

participation requires approval from the SAFE or its authorized branch.

On March 28, 2007, the

SAFE issued the Application Procedure for Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock

Holding Plans or Stock Option Plans of Overseas Listed Companies, or Notice 78.

Under Notice 78, PRC individuals who participate

in an employee stock option holding plan or a stock option plan of an overseas listed company are required, through a PRC domestic

agent or PRC subsidiary of the overseas listed company, to register with the SAFE and complete certain other procedures.

and our Chinese employees are granted shares or stock options pursuant to our share incentive plan they would be subject to Notice

However, in practice, there are significant uncertainties with regard to the interpretation and implementation of Notice 78.

We are committed to complying with the requirements of Notice 78.

However, we cannot provide

any assurance that we or our Chinese employees will be able to qualify for or obtain any registration required by Notice 78.

particular, if we and/or our Chinese employees fail to comply with the provisions of Notice 78, we and/or our Chinese employees

may be subject to fines and legal sanctions imposed by the SAFE or other PRC government authorities, as a result of which our

business operations and employee option plans could be materially and adversely affected.

M&A Rules establish more complex procedures for some acquisitions of Chinese companies by foreign investor which could make

it more difficult for us to pursue growth through acquisitions in China.

New M&A Rules that became effective on September 8, 2006 established additional procedures and requirements that could make

merger and acquisition activities by foreign investors more time-consuming and complex, including requirements in some instances

that the Ministry of Commerce be notified in advance of any change- of-control transaction in which a foreign investor takes control

of a PRC domestic enterprise.

Complying with the requirements of the M&A Rules to complete such transactions could be time-consuming,

and any required approval processes, including obtaining approval from the Ministry of Commerce, may delay or inhibit our ability

to complete such transactions, which could materially adversely affect our ability to grow our business through acquisitions in

control of currency conversion and future movements in exchange rates may adversely affect our operations and financial results.

value of the Renminbi, or RMB, the main currency used in China, fluctuates and is affected by, among other things, changes in

China’s political and economic conditions.

However, we cannot provide any assurance that we or our Chinese

employees will be able to qualify for or obtain any registration required by Notice 78.

In particular, if we and/or our Chinese

employees fail to comply with the provisions of Notice 78, we and/or our Chinese employees may be subject to fines and legal sanctions

imposed by the SAFE or other PRC government authorities, as a result of which our business operations and employee option plans

could be materially and adversely affected.

The new M&A Rules establish more complex

procedures for some acquisitions of Chinese companies by foreign investor which could make it more difficult for us to pursue growth

through acquisitions in China.

The New M&A Rules that

became effective on September 8, 2006 established additional procedures and requirements that could make merger and acquisition

activities by foreign investors more time-consuming and complex, including requirements in some instances that the Ministry of

Commerce be notified in advance of any change- of-control transaction in which a foreign investor takes control of a PRC domestic

Complying with the requirements of the M&A Rules to complete such transactions could be time-consuming, and any

required approval processes, including obtaining approval from the Ministry of Commerce, may delay or inhibit our ability to complete

such transactions, which could materially adversely affect our ability to grow our business through acquisitions in China.

Government control of currency conversion

and future movements in exchange rates may adversely affect our operations and financial results.

The value of the Renminbi,

or RMB, the main currency used in China, fluctuates and is affected by, among other things, changes in China’s political

and economic conditions.

The conversion of RMB into foreign currencies such as the U.S.

dollar have generally

been based on rates set by the People’s Bank of China, which are set daily based on the previous day’s interbank foreign

exchange market rates and current exchange rates on the world financial markets.

Foreign exchange transactions continue to be

subject to significant foreign exchange controls and require the approval of the State Administration of Foreign Exchange in China.

These limitations could affect our ability to obtain foreign exchange through debt or equity financing, or to obtain foreign exchange

for capital expenditures.

Chinese government controls its foreign currency reserves through restrictions on imports and conversion of RMB into foreign currency.

In July 2005, the Chinese government has adjusted its exchange rate policy from “Fixed Rate”

dollar have generally been based on rates

set by the People’s Bank of China, which are set daily based on the previous day’s interbank foreign exchange market

rates and current exchange rates on the world financial markets.

Foreign exchange transactions continue to be subject to significant

foreign exchange controls and require the approval of the State Administration of Foreign Exchange in China.

These limitations

could affect our ability to obtain foreign exchange through debt or equity financing, or to obtain foreign exchange for capital

expenditures.

The Chinese government

controls its foreign currency reserves through restrictions on imports and conversion of RMB into foreign currency.

In July 2005,

the Chinese government has adjusted its exchange rate policy from “Fixed Rate”

to “Floating Rate”.

Between July 2005 to December 2017, the exchange rate between the RMB and the U.S.

dollar appreciated from RMB1.00 to $0.1205

to RMB1.00 to $0.1513.

July 2005 to December 2017, the exchange rate between the RMB and the U.S.

dollar appreciated from RMB1.00 to $0.1205 to RMB1.00

Any significant appreciation of the RMB may adversely affect our operations and financial results.

Related to Our Securities

of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders.

common stock has been listed on the Nasdaq Capital Market under the symbol “AVCO”

Risks Related to Our Securities

The price of our common stock may be volatile

and fluctuate substantially, which could result in substantial losses for our stockholders.

Our common stock has been

listed on the Nasdaq Capital Market under the symbol “AVCO”

since November 5, 2018.

shares were traded previously on the OTC Market Group Inc.’s Venture Market (the “OTCQB”) since February 22,

2016, under the symbol “AVCO”

Our common shares were traded previously

on the OTC Market Group Inc.’s Venture Market (the “OTCQB”) since February 22, 2016, under the symbol “AVCO”

since October 18, 2016 and “GTHC”

prior to October 18, 2016.

price of our common stock has been, and we expect it to continue to be, volatile.

The stock market in general and the market for

smaller healthcare companies in particular have experienced extreme volatility that has often been unrelated to the operating

performance of particular companies.

As a result of this volatility, you may not be able to sell your shares of common stock at

or above the price you paid for your shares of common stock.

The market price for our common stock may be influenced by many factors,

the success of competitive

products or technologies;

developments related

to our existing or any future collaborations;

regulatory or legal

developments in the United States, China and other countries;

developments or

disputes concerning patent applications, issued patents or other proprietary rights;

the recruitment

or departure of key personnel;

actual or anticipated

changes in estimates as to financial results or recommendations by securities analysts;

variations in our

financial results or those of companies that are perceived to be similar to us;

changes in the structure

of healthcare payment systems;

market conditions

in the healthcare, pharmaceutical and biotechnology sectors;

general economic,

industry and market conditions;

the other factors

described in this “Risk Factors”

sales of our common stock or securities convertible or exchangeable for our common stock may cause our stock price to decline.

our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market,

the price of our common stock could decline.

The perception in the market that these sales may occur could also cause the price

of our common stock to decline.

addition, as of December 31, 2019, 5,260,000 shares of common stock issuable upon exercise of outstanding stock options, which

will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the

lock-up agreements and Rule 144 under the Securities Act.

If the shares we may issue from time to time upon exercise of outstanding

options are sold, or if it is perceived that they will be sold, by the award recipients in the public market, the price of our

common stock could decline.

experience dilution of your ownership interests because of the future issuance of additional shares of our common or preferred

stock or other securities that are convertible into or exercisable for our common or preferred stock.

the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership

interests of our stockholders.

We are authorized to issue an aggregate of 490,000,000 shares of common stock and 10,000,000 shares

of “blank check”

The price of our common

stock has been, and we expect it to continue to be, volatile.

The stock market in general and the market for smaller healthcare

companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular

As a result of this volatility, you may not be able to sell your shares of common stock at or above the price you paid

for your shares of common stock.

The market price for our common stock may be influenced by many factors, including:

the success of competitive products or technologies;

developments related to our existing or any future collaborations;

regulatory or legal developments in the United States, China and other countries;

developments or disputes concerning patent applications, issued patents or other proprietary rights;

the recruitment or departure of key personnel;

actual or anticipated changes in estimates as to financial results or recommendations by securities analysts;

variations in our financial results or those of companies that are perceived to be similar to us;

changes in the structure of healthcare payment systems;

market conditions in the healthcare, pharmaceutical and biotechnology sectors;

general economic, industry and market conditions;

the other factors described in this “Risk Factors”

Future sales of our common stock or securities

convertible or exchangeable for our common stock may cause our stock price to decline.

If our existing stockholders

sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the price of our common stock

could decline.

The perception in the market that these sales may occur could also cause the price of our common stock to decline.

In addition, as of December

31, 2020, 7,140,000 shares of common stock issuable upon exercise of outstanding stock options, which will become eligible for

sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule

144 under the Securities Act.

If the shares we may issue from time to time upon exercise of outstanding options are sold, or if

it is perceived that they will be sold, by the award recipients in the public market, the price of our common stock could decline.

You may experience dilution of your ownership

interests because of the future issuance of additional shares of our common or preferred stock or other securities that are convertible

into or exercisable for our common or preferred stock.

In the future, we may issue

our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our stockholders.

We are authorized to issue an aggregate of 490,000,000 shares of common stock and 10,000,000 shares of “blank check”

preferred stock.

We may issue additional shares of our common stock or other securities that are

convertible into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions, future

sales of our securities for capital raising purposes, or for other business purposes.

The future issuance of any such additional

shares of our common stock may create downward pressure on the trading price of the common stock.

We expect we will need to raise

additional capital in the near future to meet our working capital needs, and there can be no assurance that we will not be required

to issue additional shares, warrants or other convertible securities in the future in conjunction with these capital raising efforts,

including at a price (or exercise prices) below the price you paid for your stock.

of our Board of Directors to issue additional stock may prevent or make more difficult certain transactions, including a sale

Board of Directors is authorized to issue up to 10,000,000 shares of preferred stock with powers, rights and preferences designated

Shares of voting or convertible preferred stock could be issued, or rights to purchase such shares could be issued, to

create voting impediments or to frustrate persons seeking to effect a takeover or otherwise gain control of us.

The ability of

the Board of Directors to issue such additional shares of preferred stock, with rights and preferences it deems advisable, could

discourage an attempt by a party to acquire control of us by tender offer or other means.

Such issuances could therefore deprive

stockholders of benefits that could result from such an attempt, such as the realization of a premium over the market price for

their shares in a tender offer or the temporary increase in market price that such an attempt could cause.

Moreover, the issuance

of such additional shares of preferred stock to persons friendly to the Board of Directors could make it more difficult to remove

incumbent managers and directors from office even if such change were to be favorable to stockholders generally.

as an emerging growth company may result in reduced disclosure obligations.

are an “emerging growth company,”

as defined in the Jumpstart Our Business Startups Act, which we refer to as the

JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting and financial disclosure requirements

that are applicable to other public companies, that are not emerging growth companies, including, but not limited to, (1) not

being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley

Act, (2) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and (3)

exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of

any golden parachute payments not previously approved.

We may issue additional shares of our common stock or other securities that are convertible into or exercisable

for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities for

capital raising purposes, or for other business purposes.

The future issuance of any such additional shares of our common stock

may create downward pressure on the trading price of the common stock.

We expect we will need to raise additional capital in the

near future to meet our working capital needs, and there can be no assurance that we will not be required to issue additional shares,

warrants or other convertible securities in the future in conjunction with these capital raising efforts, including at a price

(or exercise prices) below the price you paid for your stock.

The ability of our Board of Directors to

issue additional stock may prevent or make more difficult certain transactions, including a sale or merger.

Our Board of Directors

is authorized to issue up to 10,000,000 shares of preferred stock with powers, rights and preferences designated by it.

of voting or convertible preferred stock could be issued, or rights to purchase such shares could be issued, to create voting impediments

or to frustrate persons seeking to effect a takeover or otherwise gain control of us.

The ability of the Board of Directors to

issue such additional shares of preferred stock, with rights and preferences it deems advisable, could discourage an attempt by

a party to acquire control of us by tender offer or other means.

Such issuances could therefore deprive stockholders of benefits

that could result from such an attempt, such as the realization of a premium over the market price for their shares in a tender

offer or the temporary increase in market price that such an attempt could cause.

Moreover, the issuance of such additional shares

of preferred stock to persons friendly to the Board of Directors could make it more difficult to remove incumbent managers and

directors from office even if such change were to be favorable to stockholders generally.

Our status as an emerging growth company

may result in reduced disclosure obligations.

We are an “emerging

growth company,”

as defined in the Jumpstart Our Business Startups Act, which we refer to as the JOBS Act, and we are eligible

to take advantage of certain exemptions from various reporting and financial disclosure requirements that are applicable to other

public companies, that are not emerging growth companies, including, but not limited to, (1) not being required to comply with

the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, (2) reduced disclosure

obligations regarding executive compensation in our periodic reports and proxy statements, and (3) exemptions from the requirements

of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not

previously approved.

We intend to take advantage of these exemptions.

Because of the reduced

disclosure and because a portion of our business is conducted in China, investors may find investing in our common stock less

attractive as a result, which could have an adverse effect on our stock price.

addition, Section 102 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition

period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting

As a result, an emerging growth company can delay the adoption of certain accounting standards until those standards

would otherwise apply to private companies.

We elected to opt out of such extended transition period and acknowledge such election

is irrevocable pursuant to Section 107 of the JOBS Act.

could remain an emerging growth company for up to five years, or until the earliest of (1) the last day of the first fiscal year

in which our annual gross revenues exceed $1.07 billion, (2) the date that we become a “large accelerated filer”

defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our ordinary shares that is held by non-affiliates

exceeds $700 million as of the last business day of our most recently completed second fiscal quarter and we have been publicly

reporting for at least 12 months, or (3) the date on which we have issued more than $1 billion in non-convertible debt during

the preceding three-year period.

a “smaller reporting company,”

and we cannot be certain if the reduced disclosure requirements applicable to smaller

reporting companies will make our common stock less attractive to investors.

are currently a “smaller reporting company”, meaning that we are not an investment company, an asset- backed issuer,

or a majority-owned subsidiary of a parent company that is not a smaller reporting company and have a non-affiliated public float

of less than $250.0 million and annual revenues of less than $100.0 million during the most recently completed fiscal year and

no public float or a public float less than $700 million.

In the event that we are still considered a “smaller reporting

company,”

at such time as we cease being an “emerging growth company,”

we will be required to provide additional

disclosure in our SEC filings.

However, similar to an “emerging growth companies”, “smaller reporting companies”

Because of the reduced disclosure and because a portion of

our business is conducted in China, investors may find investing in our common stock less attractive as a result, which could have

an adverse effect on our stock price.

In addition, Section 102

of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in

Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards.

an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to

private companies.

We elected to opt out of such extended transition period and acknowledge such election is irrevocable pursuant

to Section 107 of the JOBS Act.

We could remain an emerging

growth company for up to five years, or until the earliest of (1) the last day of the first fiscal year in which our annual gross

revenues exceed $1.07 billion, (2) the date that we become a “large accelerated filer”

as defined in Rule 12b-2 under

the Exchange Act, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million

as of the last business day of our most recently completed second fiscal quarter and we have been publicly reporting for at least

12 months, or (3) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year

We are a “smaller reporting company,”

and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common

stock less attractive to investors.

We are currently a “smaller reporting company”,

meaning that we are not an investment company, an asset- backed issuer, or a majority-owned subsidiary of a parent company that

is not a smaller reporting company and have a non-affiliated public float of less than $250.0 million and annual revenues of less

than $100.0 million during the most recently completed fiscal year and no public float or a public float less than $700 million.

“Smaller reporting companies”

are able to provide simplified executive compensation disclosures in their filings;

are exempt from the provisions of Section

404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on

the effectiveness of internal control over financial reporting;

and have certain other decreased disclosure obligations in their

SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual

Decreased disclosures in our SEC filings due to our status as a “smaller reporting company”

may make it harder

for investors to analyze our results of operations and financial prospects.

If securities

or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion

regarding our stock, our stock price and trading volume could decline.

trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish

about us or our business.

exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting

firms provide an attestation report on the effectiveness of internal control over financial reporting;

and have certain other decreased

disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited

financial statements in annual reports.

Decreased disclosures in our SEC filings due to our status as a “smaller reporting

company”

may make it harder for investors to analyze our results of operations and financial prospects.

If securities or industry analysts do not

publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock

price and trading volume could decline.

The trading market for

our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.

We do not currently have and may never obtain research coverage by securities and industry analysts.

If no or few securities or industry analysts commence coverage of us, the trading price for our stock would be negatively impacted.

In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading

opinion regarding us, our business model, our intellectual property or our stock performance, or if our operating results fail

to meet the expectations of analysts, our stock price would likely decline.

If one or more of these analysts cease coverage of

us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our

stock price or trading volume to decline.

Our officers,

directors and principal stockholders own a significant percentage of our stock and will be able to exert significant control over

matters subject to stockholder approval.

officers, directors and 5% stockholders and their affiliates beneficially own a significant percentage of our outstanding common

As a result, these stockholders have significant influence and may be able to determine all matters requiring stockholder

For example, these stockholders may be able to control elections of directors, amendments of our organizational documents,

or approval of any merger, sale of assets, or other major corporate transactions.

This concentration of ownership could delay

or prevent any acquisition of our company on terms that other stockholders may desire, and may adversely affect the market price

of our common stock.

be exposed to additional risks as a result of “going public”

If no or few securities or

industry analysts commence coverage of us, the trading price for our stock would be negatively impacted.

In the event we obtain

securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us,

our business model, our intellectual property or our stock performance, or if our operating results fail to meet the expectations

of analysts, our stock price would likely decline.

If one or more of these analysts cease coverage of us or fail to publish reports

on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume

Our officers, directors and principal stockholders

own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our officers, directors

and 5% stockholders and their affiliates beneficially own a significant percentage of our outstanding common stock.

these stockholders have significant influence and may be able to determine all matters requiring stockholder approval.

these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any

merger, sale of assets, or other major corporate transactions.

This concentration of ownership could delay or prevent any acquisition

of our company on terms that other stockholders may desire, and may adversely affect the market price of our common stock.

We may be exposed to additional risks as

a result of “going public”

by means of a reverse acquisition transaction.

may be exposed to additional risks because we became a public company through a “reverse merger”

has been increased focus by government agencies on reverse merger transactions in recent years, and we may be subject to increased

scrutiny by the SEC and other government agencies and holders of our securities as a result of the completion of our reverse merger

Additionally, our “going public”

by means of a reverse merger transaction may make it more difficult

for us to obtain coverage from securities analysts of major brokerage firms following the reverse merger transaction because there

may be little incentive to those brokerage firms to recommend the purchase of our common stock.

Further, investment banks may

be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company

by means of an initial public offering because they may be less familiar with our company as a result of more limited coverage

by analysts and the media, and because we became public at an early stage in our development.

The failure to receive research

coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our

We may be exposed to additional

risks because we became a public company through a “reverse merger”

There has been increased focus by

government agencies on reverse merger transactions in recent years, and we may be subject to increased scrutiny by the SEC and

other government agencies and holders of our securities as a result of the completion of our reverse merger transaction.

Additionally,

our “going public”

by means of a reverse merger transaction may make it more difficult for us to obtain coverage from

securities analysts of major brokerage firms following the reverse merger transaction because there may be little incentive to

those brokerage firms to recommend the purchase of our common stock.

Further, investment banks may be less likely to agree to underwrite

secondary offerings on our behalf than they might if we became a public reporting company by means of an initial public offering

because they may be less familiar with our company as a result of more limited coverage by analysts and the media, and because

we became public at an early stage in our development.

The failure to receive research coverage or support in the market for our

shares will have an adverse effect on our ability to develop a liquid market for our common stock.

The occurrence of any such event

could cause our business or stock price to suffer.

We do not anticipate paying dividends on

our common stock, and investors may lose the entire amount of their investment.

We have never declared

or paid cash dividends on our common stock, and we do not anticipate such a declaration or payment for the foreseeable future.

We expect to use future

earnings, if any, to fund business growth.

Therefore, stockholders will not receive any funds absent a sale of their shares of

common stock.

The occurrence of any such event could cause our business or stock price to suffer.

not anticipate paying dividends on our common stock, and investors may lose the entire amount of their investment.

have never declared or paid cash dividends on our common stock, and we do not anticipate such a declaration or payment for the

foreseeable future.

expect to use future earnings, if any, to fund business growth.

Therefore, stockholders will not receive any funds absent a sale

of their shares of common stock.

We cannot assure stockholders of a positive return on their investment when they sell their shares,

nor can we assure that stockholders will not lose the entire amount of their investment.

regulatory requirements, including those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for

us to retain or attract qualified officers and directors, which could adversely affect the management of our business and our

ability to obtain or retain listing of our common stock on a national securities exchange.

may be unable to attract and retain those qualified officers, directors and members of board committees required to provide for

effective management because of the rules and regulations that govern publicly held companies, including, but not limited to,

certifications by principal executive officers.

The enactment of the Sarbanes-Oxley Act has resulted in the issuance of a series

of related rules and regulations and the strengthening of existing rules and regulations by the SEC, as well as the adoption of

new and more stringent rules by national securities exchanges.

The perceived increased personal risk associated with these changes

may deter qualified individuals from accepting roles as directors and executive officers.

some of these changes heighten the requirements for board or committee membership, particularly with respect to an individual’s

independence from the corporation and level of experience in finance and accounting matters.

We may have difficulty attracting

and retaining directors with the requisite qualifications.

If we are unable to attract and retain qualified officers and directors,

the management of our business and our ability to obtain or retain listing of our shares of common stock on any national securities

exchange could be adversely affected.

cannot satisfy, or continue to satisfy, the initial listing requirements and other rules of the Nasdaq Capital Market, our securities

may be delisted, which could negatively impact the price of our securities and your ability to sell them.

common stock has been listed on the Nasdaq Capital Market under the symbol “AVCO”

We cannot assure stockholders of a positive return on their investment when they sell their shares, nor can we assure

that stockholders will not lose the entire amount of their investment.

Applicable regulatory requirements, including

those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for us to retain or attract qualified

officers and directors, which could adversely affect the management of our business and our ability to obtain or retain listing

of our common stock on a national securities exchange.

We may be unable to attract

and retain those qualified officers, directors and members of board committees required to provide for effective management because

of the rules and regulations that govern publicly held companies, including, but not limited to, certifications by principal executive

The enactment of the Sarbanes-Oxley Act has resulted in the issuance of a series of related rules and regulations and

the strengthening of existing rules and regulations by the SEC, as well as the adoption of new and more stringent rules by national

securities exchanges.

The perceived increased personal risk associated with these changes may deter qualified individuals from

accepting roles as directors and executive officers.

Further, some of these

changes heighten the requirements for board or committee membership, particularly with respect to an individual’s independence

from the corporation and level of experience in finance and accounting matters.

We may have difficulty attracting and retaining

directors with the requisite qualifications.

If we are unable to attract and retain qualified officers and directors, the management

of our business and our ability to obtain or retain listing of our shares of common stock on any national securities exchange could

be adversely affected.

If we cannot satisfy, or continue to satisfy,

the initial listing requirements and other rules of the Nasdaq Capital Market, our securities may be delisted, which could negatively

impact the price of our securities and your ability to sell them.

Our common stock has been

listed on the Nasdaq Capital Market under the symbol “AVCO”

since November 5, 2018.

to maintain our listing on the Nasdaq Capital Market, we are required to comply with certain rules of the applicable trading market,

including those regarding minimum stockholders’

In order to maintain our listing

on the Nasdaq Capital Market, we are required to comply with certain rules of the applicable trading market, including those regarding

minimum stockholders’

equity, minimum share price and certain corporate governance requirements.

We may not be able to continue to satisfy the listing requirements and other applicable rules of the Nasdaq Capital Market.

we are unable to satisfy the criteria for maintaining our listing, our securities could be subject to delisting.

our common stock is delisted from trading by the applicable trading market we could face significant consequences, including.

a limited availability

for market quotations for our securities;

reduced liquidity

with respect to our securities;

a determination

that our common stock is a “penny stock,”

which will require brokers trading in our common stock to adhere to

more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common

limited amount of

news and analyst coverage;

a decreased ability

to issue additional securities or obtain additional financing in the future.

be subject to securities class action litigation.

the past, securities class action litigation has often been brought against a company following a decline in the market price

of its securities.

This risk is especially relevant for us because companies in our industry have experienced significant stock

price volatility in recent years.

If we face such litigation, it could result in substantial costs and a diversion of management’s

attention and resources, which could harm our business.

We may not be able to continue

to satisfy the listing requirements and other applicable rules of the Nasdaq Capital Market.

If we are unable to satisfy the criteria

for maintaining our listing, our securities could be subject to delisting.

If our common stock is

delisted from trading by the applicable trading market we could face significant consequences, including.

a limited availability for market quotations for our securities;

reduced liquidity with respect to our securities;

a determination that our common stock is a “penny stock,”

which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock;

limited amount of news and analyst coverage;

a decreased ability to issue additional securities or obtain additional financing in the future.

We could be subject to securities class

action litigation.

In the past, securities

class action litigation has often been brought against a company following a decline in the market price of its securities.

risk is especially relevant for us because companies in our industry have experienced significant stock price volatility in recent

If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources,

which could harm our business.

UNRESOLVED STAFF COMMENTS

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors